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Bacterial infections are becoming more difficult to treat, due to the emergence of 
resistance strains to almost every antibiotic. Most bacteria that infect humans to cause 
diseases are biofilm forming bacteria and it has been shown that most antibiotics that 
are in clinical use today are not very effective against bacteria in a biofilm. Despite 
the difficulty in eradicating bacterial biofilms, there is no anti-biofilm drug in clinical 
use today. Cyclic diguanylate (c-di-GMP) is a second messenger in bacteria and it 
that is synthesized in the cytosol, in response to a changing bacterial environment to 
regulate bacterial physiology. Due to the central role that c-di-GMP plays in bacteria, 
there are interests in understanding c-di-GMP signaling with the hope that detailed 
understanding of c-di-GMP signaling would provide avenues to design small 
molecules that could be used to inhibit bacterial virulence and biofilm formation, 
which c-di-GMP regulates. We aim to understand the determinants of c-di-GMP 
binding to receptor proteins and RNA riboswitches, using c-di-GMP analogs. We 
  
designed a concise synthetic strategy to make c-di-GMP and analogs. These analogs 
were used to study the structure-activity-relationship (SAR) of c-di-GMP. The 
polymorphisms of the synthesized analogs were studied using a panel of 
spectroscopic techniques. It was discovered that one analog of c-di-GMP, namely 2‟-
F-c-di-GMP, which had a high propensity to exist in the closed conformation could 
potently inhibit c-di-GMP synthesis by c-di-GMP synthases. Since c-di-GMP 
promotes biofilm formation in bacteria, these analogs represent good starting points 
to design anti-biofilm agents to treat persistent bacterial infections. 
C-di-AMP was recently discovered as another important bacterial signaling molecule 
and it is mostly found in Gram-positive bacteria. C-di-AMP controls many processes 
in bacteria, including growth, cell wall synthesis, ion transport, and sporulation. Many 
of the receptor or effector proteins that mediate c-di-AMP signaling remain to be 
characterized and there is lack of knowledge regarding how environmental factors 
regulate c-di-AMP metabolism. We developed a new fluorescent probe for the “real-
time” detection of c-di-AMP. This assay could be used to find inhibitors of c-di-AMP 
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Chapter 1. C-di-GMP and c-di-AMP Signaling in Bacteria  
 
1.1 Introduction 
According to the report from World Health Organization (WHO), 80% of human 
bacterial infections are caused by biofilm-forming bacteria such as Pseudomonas 
aeruginosa, Staphylococcu aureus and Escherichia coli.
1
 Biofilm is a microbial 
derived sessile community characterized by cells that are attached to a substratum or 
interface or to each other, are embedded in a matrix of extracellular polymeric 
substances that they have produced, (see Figure 1.1 for examples of biofilm) and 
exhibit an altered phenotype with respect to growth rate and gene transcription.
2
  
Biofilms are difficult to diagnose and are resistant to antibiotic treatment.
3
 It is 
believed that the physical barrier provided by the extracellular biofilm matrix 







Figure 1.1 Examples of biofilms from various bacteria. a) Staphylococcus aureus 
biofilm on a vascular prosthesis.
8
 b) Escherichia coli biofilm in the calyx area of an 
inoculated golden delicious apple.
9
 c) Pseudomonas aeruginosa strain PA14 biofilm 




In bacteria, the cyclic dinucleotides, c-di-GMP and c-di-AMP (see Figure 1.2 for 
structures), have emerged as important second messengers involved in the regulation 
of processes that regulate virulence factor production or biofilm formation.
1,11
 
Understanding how bacteria integrate signals from various environmental factors to 
regulate the metabolism of various dinucleotide second messengers, which control 
several key processes required for adaptation is key for efforts to develop agents to 





Figure 1.2 Structures of c-di-GMP and c-di-AMP, bacterial second messengers. 
 
In general, scientists would like to control the intracellular concentrations of second 
messengers in order to prevent/disperse biofilm formation.
1
 Common approaches that 
could be used to perturb second messengers signaling pathways involve, inhibiting 
the synthesis of second messengers by suppressing the synthases and/or stimulating 
the hydrolysis of c-di-NMP via the activation of phosphodiesterases,
12-14
 inhibiting 
receptors that bind to c-di-G(A)MP, called c-di-G(A)MP effectors, using small 
molecules
15-18
 or sequestration of the receptors with designed macromolecules
19,20
. 
The Sintim group has suggested that the sequestration of c-di-G(A)MP with small 
molecules via supramolecular aggregate formation could also be a viable approach to 
inhibit c-di-G(A)MP signaling.
21,22
 Last but not least, others have also shown that 
small diffusible signals, such as NO, can perturb c-di-G(A)MP concentrations and 







1.2 C-di-GMP, a ubiquitous bacterial signaling molecule 
C-di-GMP was first discovered by Benziman and co-workers more than two decades 
ago.
26
 C-di-GMP was discovered in Acetobacter xylinum
27-29
 and it is now 
appreciated that c-di-GMP affects many processes in other bacteria, including the 
synthesis of biopolymers that are components of bacterial biofilms
29,30
 and the 
expression of virulence-associated genes.
31,32
 Because c-di-GMP plays a central role 
in bacteria, there are interests in understanding c-di-GMP signaling with the hope that 
detailed understanding of c-di-GMP signaling would provide avenues to design small 
molecules that could be used to inhibit bacterial virulence and biofilm formation, 
which c-di-GMP regulates.
11
 C-di-GMP binding proteins (effectors), such as PilZ 
domain proteins
33




 and  c-di-GMP 
riboswitches
36,37
, which are involved in the regulation of bacterial biofilms and 













Figure 1.3 Overview of c-di-GMP regulations in bacteria.
11
 Reproduced by 







1.2.1 Diguanylate cyclases 
C-di-GMP is produced from two guanosine triphosphate (GTP) molecules by 
diguanylate cyclases (DGCs), which contain the common protein domain GGDEF 
(Gly-Gly-Asp-Glu-Phe) or GGEEF (Gly-Gly-Glu-Glu-Phe).
39-41
 A DGC with 
AGDEF domain that is catalytically active has also been demonstrated in Vibrio 
cholerae.
42
 DGC proteins often contain an inhibitory site (I-site) with an RxxD motif 
(x: any amino acid). C-di-GMP synthesis is allosterically inhibited when c-di-GMP is 
bound to the I-site of some DGCs.
43
 Examples of DGCs with I-site include WspR 
from P. aeruginosa
44
 (see Figure 1.4 for a crystal structure of WspR) whereby c-di-
GMP is bound to both the active site (A-site) and allosteric site (I-site), PleD from 
Caulobacter crescentus
45
 and DgcA from Rhodobacter sphaeroides
46
. Some DGCs, 
such as XCC4471GGDEF from Xanthomonas campestris, do not possess an I-site 













C-di-GMP is broken down into 5‟-phosphoguanylyl-(3‟-5‟)-guanosine (pGpG) by 
specific phosphodiesterases (PDEs), characterized with the EAL domain.
49
 pGpG is 
then degraded further into GMP by phosphodiesterases
49
 or nano RNAses
50
. C-di-
GMP can also be cleaved directly into GMP by PDE with HD-GYP domain.
51,52
  
PDEs containing the EAL domain
44,53,54

















 Although several 
crystal structures of PDE enzymes have now been solved (see Figure 1.5 for a few 
examples),
58,59
 the cleavage mechanisms of EAL containing PDEs have not been fully 
elucidated because crystal structures only give static pictures. HD-GYP-containing 
PDEs have proven difficult to crystallize and hence there is a paucity of high 
resolution HD-GYP PDE crystal structures.
60,61
 The crystal structure of a catalytically 
inactive HD-GYP constaining PDE, BD1817 from Bdellovibrio bacteriovorus, has 
been solved.
60,61




 center is found in the 
active site.
60
 Recently, the crystal structure of a catalytically active HD-GYP domain 
protein from Persephonella marina (PmGH) was revealed.
52
 Bellini et al. 
demonstrated a novel trinuclear iron arranged in a triangular geometry in the binding 
site of the HD-GYP domain from P. marina with a single and “closed” form of c-di-
GMP.  C-di-GMP interacts with the central Fe ion in PmGH via one of the exocyclic 
phosphate oxygens. The other exocyclic phosphate oxygen is involved in hydrogen 
bonding with a tyrosine residue. The c-di-GMP nucleobase also makes key 
interactions with lysine and arginine residues (see Figure 1.6). Interestingly, the 




proficiency of the enzyme and so it is unclear if these residues play any role during 
catalysis.
52,61
 It would have been instructive if the authors of the PmGH paper had 
investigated the selectivity of the PmGH mutants with other cyclic dinucleotides, 
such as c-di-AMP to find out if the GYP motif served as a selectivity motif.  
 
Figure 1.5 (a) crystal structure of c-di-GMP PDE YahA (PDB code: 4LJ3
59
); (b) 







Figure 1.6 (a) GMP as hydrolysis product, bound to PmGH; (b) c-di-GMP as 
substrate, bound to PmGH; (c) surface representation of c-di-GMP bound to PmGH; 
(d) superposition of the structures of PmGH bound to cyclic di-GMP and GMP (PDB 
code: 4ME4
52
). Reproduced with permission from John Wiley & Sons Ltd.
52
 
The activity of some c-di-GMP phosphodiesterases can be modulated by 
environmental factors.
55,62,63
 For example, Jenal has shown that the PDE CC3396, 
characterized with GGDEF-EAL domain, can be regulated by GTP. When the 
concentration of GTP is elevated, an allosteric site in CC3396 becomes occupied with 







1.2.3 C-di-GMP binding to effector proteins 
As a second messenger, the major function of c-di-GMP is to relay signals by binding 
to different receptors in order to regulate functions like biofilm formation.
1,11
 C-di-
GMP receptors can be categorized
11,64
 into four groups: a) PilZ domain proteins, 
which was the first c-di-GMP receptor protein identified and later proved to exist in 
various bacterial species
32,65,66
; b) I-site on DGCs
67,68





 domain or proteins with degenerate GGDEF-EAL domain
34,67,68,70,71
; c) 
transcription factors like FleQ, VpsT and Clp, which binds c-di-GMP binds and affect 
gene expression
35,72,73





 upon binding to c-di-GMP. 
 
PilZ domain protein was first identified in P. aeruginosa as a protein that regulates 
pilus formation.
33
 Several crystal structures of PilZ domain proteins (VCA004280, 
PP439781 and PA460882) have now been carefully examined to demonstrate 
different binding modes between c-di-GMP and the PilZ domains (Figure 1.7a-c). 
PP4397, a prototypical PilZ domain protein undergoes a dimeric to monomeric 
transition upon binding to c-di-GMP (Figure 1.7d(i)).
75
  In another PilZ domain 
protein, VCA0042, the binding of c-di-GMP causes protein conformational change. 
(Figure 1.7d(ii)) 
76
 When c-di-GMP binds to PA4608, a PilZ domain protein found in 
P. aeruginosa, the protein undergoes a conformational change, leading to charge 
partition on the surface of the protein. Hence, the protein‟s surface becomes 
negatively charged and presumably interacts with positively charged downstream 








Figure 1.7 Crystal structures of several PilZ domain proteins bound with c-di-GMP 
and c-di-GMP modulation modes. (a) Crystal structure of PA4608 (PDB code: 
2L74
77
); (b) crystal structure of VCA0042 (PDB code: 2RDE
76
); (c) crystal structure 
of PP4397 (PDB code: 3KYF
75
); (d) Different modulation modes in changes in 
conformation or aggregation of PilZ domain proteins when bound to c-di-GMP; 
YcgR-N domain is in blue color and PilZ domain is in green color. Reproduced by 





FimX is one of the typical examples of c-di-GMP receptors with degenerate GGDEF-
EAL domains, controlling twitching motility as identified in P. aeruginosa.
44
  
Although FimX contains PDE (EAL) and DGC (GGDEF) domains, it can neither 








Recently, He and co-workers characterized a new FimX type protein, called Filp in 
Xanthomonas oryzae pv. oryzae (Xoo), commonly found as bacteria in rice. They 
also showed that this new FimX family protein interacted with a PilZ-domain protein 




The third type of c-di-GMP receptors are transcription factors, which activate the 
expression of downstream genes in response to environmental triggers. FleQ was the 
first characterized c-di-GMP transcriptional regulator found in P. aeruginosa.
35
 FleQ 
was shown to activate flagella gene expression in the absence of c-di-GMP. Upon 
binding to c-di-GMP, FleQ no longer activates flagella genes.
78
 Recently, Harwood 
demonstrated that c-di-GMP also inhibited the ATPase activity of c-di-GMP (see 
Figure 1.8).
79
  However, more work is needed to clarify the link between the ATPase 






Figure 1.8 FleQ binds to c-di-GMP to inhibit the flagella gene expression. 




Apart from proteins, c-di-GMP also binds to RNA structures called 
riboswitches.
36,80,81
 Riboswitches are RNAs aptamer domains that bind with small 
molecule ligands to control downstream signals. There have been over 20 different 
riboswitch classes reported for specific binding with amino acids, nucleobases, 
sugars, vitamins and coenzymes.
81
 However, there are only two different classes of c-








1.2.4 Detection of c-di-GMP 
The ability of small intercalators to aggregate c-di-GMP has been investigated by the 
Sintim group to provide various detection assays that have the potential to be used in 
high-throughput screenings to discover inhibitors of c-di-GMP metabolism proteins. 
For example, c-di-GMP can aggregate into supramolecular structures when thiazole 
orange (TO) is present.
22
 TO is entrapped in a cavity (presumable G-quadruplex) 
created by c-di-GMP, leading to fluorescence enhancement (see Figure 1.9a). The 
entrapment of TO reduces the rotational freedom of this molecule and this accounts 
for the fluorescence enhancement. In another rendition of c-di-GMP aggregate 
formation facilitated by intercalators, the Sintim group demonstrated that a G-
quadruplex that form from c-di-GMP/proflavine associations can enhance the 
peroxidation proficiency of hemin, see Figure 1.9b.
82
 Sen and co-workers showed in 
the late 90‟s that DNA G-quadruplexes can act peroxidase mimics and these are 
referred as peroxidase DANzymes.
83
 In analogy to DNAzymes, Sintim et al. referred 
to a c-di-GMP/proflavine hemin complex as a nucleotidezyme.
82
 The formation of a 
c-di-GMP nucleotidezyme facilities a colorimetric detection of c-di-GMP using 
ABTS and H2O2.
82,84,85






Figure 1.9 (a) Colorimetric and (b) fluorescent detection of c-di-GMP utilizing 










A sensitive detection of c-di-GMP (nanomolar) using conditioned aptamer strategy 
has also been disclosed by the Sintim group (see Figure 1.10).
86
 In this approach, an 
aptamer module that binds to the fluorogenic small molecule 3,5-difluoro-4-
hydroxybenzylidene imidazolinone (DFHBI), also called Spinach, was fused to a c-
di-GMP binding module. Binding of c-di-GMP to its aptamer module facilitated the 
binding of spinach to its aptamer module, leading to the enhancement of the 
fluorescence of spinach.
86
   
 
The various detection assays for c-di-GMP are currently being used by the Sintim 
group to study how environmental factors affect the intracellular concentrations of c-
di-GMP in bacteria. Additionally, these assays are being utilized by others to discover 







Figure 1.10 Nanomolar detection of c-di-GMP using an aptamer tethered to a 
Spinach RNA. 
1.2.5 Inhibitors of c-di-GMP receptors 
C-di-GMP is crucial in biofilms formation and hence there have been efforts to 
develop/discover small molecules that inhibit c-di-GMP signaling. So far, efforts 
have mainly been focused on the inhibition of c-di-GMP synthase DGC (see Figure 







Figure 1.11 Structures of small molecules identified as DGC inhibitors.
87-93
 
Table 1.1 Summary of small molecules identified as DGC inhibitors. 










    
2'-F-c-di-GMP (Chapter 2, 
2.3) 






    
Papulacandin B (1.3) Inhibit DGC (A. xylinum dgc) 70
*
 88 
    
Glycosidic triterpenoid 
saponin (GTS) (1.4) 
Inhibit DGC (A. xylinun dgc) 5
*
 89 




Inhibit DGC (VC2370) 1 90 
 Inhibit DGC (WspR) 17.8 90 
    
LP-3134 (1.6) 
Inhibit DGC (WspR) 
44.9 91 
LP-3145 (1.7) 70.9 91 
LP-4010 (1.8) 102.4 91 
LP-1062 (1.9) 73.1 91 
    
Sulfathiazole (1.10) Inhibit DGC (WspR) 5.8 92 
    
Azathioprine (1.11) Inhibit DGC (WspR) 40 93 
 Inhibit DGC (YdaM) 270 93 
    
Ebselen (1.12) Inhibit DGC (WspR) 13.6 87 
 Inhibit DGC (PelD) 5 87 
 
In 1998, Benziman and co-workers identified two glycosylated triterpenoid saponins 
(GTS) as specific inhibitors of diguanylate cyclase in Acetobacter xylinum.  However, 
these triterpenoid molecules are relatively large and not drug-like molecules. No 




After over two decades, Waters and co-workers reported several small molecules, 
including N-(4-anilinophenyl)benzamide and LP-3145 as potential DGC inhibitors to 











 reduced E. 
coli biofilm via the inhibition of DGC (WspR), which leads to a lowering of 
intracellular c-di-GMP. Of note, azathioprine is used as anti-inflammatory drug in the 
treatment of Crohn‟s disease and rheumatoid arthritis. Therefore, its toxicity profile 
has already been known and could become a safe anti-biofilm drug to use in clinic. 
Recently, Lee and co-workers reported that ebselen inhibits DGC (WspR), via 
covalent modification of a cystein group mear the active site.
87
 Ebselen is however an 
alkylating agent as well as a planar aromatic molecule which may not be an ideal 
drug candidate due to the potential toxicity.
94
   
 
1.2.6 Polymorphism of c-di-GMP  
Almost a decade ago, Jones and co-workers showed that in solution phase, millimolar 
c-di-GMP could readily form dimers, tetraplexes and higher aggregates in the 
presence of cations.
95,96
 Divalent cations such as magnesium promote dimer 
formation in c-di-GMP whereas monovalent cations such as potassium promote the 
formation of tetraplexes and octaplexes in c-di-GMP
95,96
 (see Figure 1.12). We have 
shown that a conservative change to the structure of c-di-GMP  by replacing an 
endocyclic oxygen with sulfur to give an analog called endo-S-c-di-GMP (see Figure 
1.13) dramatically diminishes the propensity to form G-quadruplexes or higher 
aggregation, implying that c-di-GMP is finely poised to respond to environmental 
changes via changes in polymorphism.
15
 The intracellular concentration of c-di-GMP 
is however up to 10 μM but even at 100 μM, c-di-GMP mainly exists as a 
monomer/dimer mixture.
97




of c-di-GMP was questioned by the Sintim group.
15,21,22,98
 Between 2011-2012, 
Sintim and co-workers published a series of papers that demonstrated that at 
physiological relevant concentrations of c-di-GMP (as low as 5 μM), c-di-GMP could 
form higher order aggregates when certain aromatic compounds, such as acridines 
and cyanines were present.
21,22,98
 This propensity of c-di-GMP to form tetraplexes or 
octaplexes (G-quadruplexes) or even higher order structures at micromolar 




, which are found in vivo 
is intriguing as simple nucleotides (such as GTP or pGpG) do not readily form G-
quadruplex structures at micromolar concentrations. Plausibly, the facile 
interconversion of c-di-GMP into different aggregation states could be a means 
whereby bacteria regulate biofilms formation in the presence of different metals.  
 
Figure 1.12 Proposed model of polymorphism of c-di-GMP in presence of cations or 







Figure 1.13 Structure of endo-S-c-di-GMP. 
 
During my PhD, I was interested in understanding or deciphering the moieties on c-
di-GMP that are important for binding to different receptors. In Chapter 2, my 
published manuscript describing 2‟-modified analogs of c-di-GMP and binding to 
protein receptors is presented. In Chapter 3, my published manuscript describing both 













1.3 C-di-AMP, another ubiquitous and important signaling molecule 
Cyclic-di-adenosine monophosphate (c-di-AMP) is a recently discovered bacterial 
signaling molecule. It was originally discovered during the structural elucidation of 
the Bacillus subtilis sporulation checkpoint protein, DisA, by Hopfner and co-
workers.
99
 C-di-AMP has now been shown to be involved in regulating cell size
100
, 




 and sensing the DNA 
damage
103
 (see Figure 1.14). Recent studies have suggested that c-di-AMP is as 
ubiquitous in Gram-positive bacteria as c-di-GMP in Gram-negative bacteria.
99,104 
 
Figure 1.14 Overview of c-di-AMP functions in bacteria.
 
 
Although the metabolism proteins and “adaptor/effector” proteins for c-di-AMP 
remain largely uncharacterized, efforts towards the quantitative detection of c-di-
AMP in vitro and in vivo would aid the characterization of c-di-AMP receptors would 




In Chapter 4, I described a new assay that I developed to detect c-di-AMP in real time 
(see Figure 1.15).  This new assay for detecting c-di-AMP has the potential to 




Figure 1.15 Schematic illustration of detection of c-di-AMP by coralyne assay. 


















References and Notes 
1 Römling, U.; Balsalobre, C. J. Intern. Med. 2012, 272, 541. 
2 Donlan, R. M.; Costerton, J. W. Clin. Microbiol. Rev. 2002, 15, 167. 
3 Sintim, H. O.; Al Smith, J.; Wang, J.; Nakayama, S.; Yan, L. Future Med. 
Chem. 2010, 2, 1005. 
4 Duguid, I. G.; Evans, E.; Brown, M. R.; Gilbert, P. J. Antimicrob. Chemother. 
1992, 30, 803. 
5 Hoyle, B. D.; Wong, C. K.; Costerton, J. W. Can. J. Microbiol. 1992, 38, 
1214. 
6 Suci, P. A.; Mittelman, M. W.; Yu, F. P.; Geesey, G. G. Antimicrob. Agents. 
Chemother. 1994, 38, 2125. 
7 Musk, D. J.; Hergenrother, P. J. Curr. Med. Chem. 2006, 13, 2163. 





accessed on Apr 17
th
, 2014. 




11 Kalia, D.; Merey, G.; Nakayama, S.; Zheng, Y.; Zhou, J.; Luo, Y.; Guo, M.; 
Roembke, B. T.; Sintim, H. O. Chem. Soc. Rev. 2013, 42, 305. 
12 Purcell, E. B.; McKee, R. W.; McBride, S. M.; Waters, C. M.; Tamayo, R. J. 
Bacteriol. 2012, 194, 3307. 
13 An, S.; Wu, J.; Zhang, L. H. Appl. Environ. Microbiol. 2010, 76, 8160. 
14 Roy, A. B.; Petrova, O. E.; Sauer, K. J. Bacteriol. 2012, 194, 2904. 
15 Wang, J.; Zhou, J.; Donaldson, G. P.; Nakayama, S.; Yan, L.; Lam, Y.-f.; Lee, 
V. T.; Sintim, H. O. J. Am. Chem. Soc. 2011, 133, 9320. 
16 Zhou, J.; Watt, S.; Wang, J.; Nakayama, S.; Sayre, D. A.; Lam, Y. F.; Lee, V. 
T.; Sintim, H. O. Bioorg. Med. Chem. 2013, 21, 4396. 
17 Kumagai, Y.; Matsuo, J.; Hayakawa, Y.; Rikihisa, Y. J. Bacteriol. 2010, 192, 
4122. 
18 Shanahan, C. A.; Gaffney, B. L.; Jones, R. A.; Strobel, S. A. Biochemistry 
2013, 52, 365. 
19 Ma, Q.; Yang, Z.; Pu, M.; Peti, W.; Wood, T. K. Environ. Microbiol. 2011, 
13, 631. 
20 Wexselblatt, E.; Katzhendler, J.; Saleem-Batcha, R.; Hansen, G.; Hilgenfeld, 
R.; Glaser, G.; Vidavski, R. R. Bioorg. Med. Chem. 2010, 18, 4485. 
21 Nakayama, S.; Kelsey, I.; Wang, J. X.; Sintim, H. O. Chem. Comm.2011, 47, 
4766. 
22 Nakayama, S.; Kelsey, I.; Wang, J.; Roelofs, K.; Stefane, B.; Luo, Y.; Lee, V. 
T.; Sintim, H. O. J. Am. Chem. Soc. 2011, 133, 4856. 
23 Barraud, N.; Storey, M. V.; Moore, Z. P.; Webb, J. S.; Rice, S. A.; Kjelleberg, 
S. Microb. Biotechnol. 2009, 2, 370. 
24 Carlson, H. K.; Vance, R. E.; Marletta, M. A. Mol. Microbiol. 2010. 
25 Liu, N.; Xu, Y.; Hossain, S.; Huang, N.; Coursolle, D.; Gralnick, J. A.; Boon, 




26 Ross, P.; Weinhouse, H.; Aloni, Y.; Michaeli, D.; Weinberger-Ohana, P.; 
Mayer, R.; Braun, S.; de Vroom, E.; van der Marel, G. A.; van Boom, H. H.; 
Benziman, M. Nature 1987, 325, 279. 
27 Römling, U.; Gomelsky, M.; Galperin, M. Y. Mol. Microbiol. 2005, 57, 629. 
28 Sondermann, H.; Shikuma, N. J.; Yildiz, F. H. Curr. Opin. Microbiol. 2012, 
15, 140. 
29 Hengge, R. Nat. Rev. Drug Discov. 2009, 7, 263. 
30 Wolfe, A. J.; Visick, K. L. J. Bacteriol. 2008, 190, 463. 
31 Tamayo, R.; Pratt, J. T.; Camilli, A. Annu. Rev. Microbiol. 2007, 61, 131. 
32 Pratt, J. T.; Tamayo, R.; Tischler, A. D.; Camilli, A. J. Biol. Chem. 2007, 282, 
12860. 
33 Alm, R. A.; Bodero, A. J.; Free, P. D.; Mattick, J. S. J. Bacteriol. 1996, 178, 
46. 
34 Krasteva, P. V.; Fong, J. C.; Shikuma, N. J.; Beyhan, S.; Navarro, M. V.; 
Yildiz, F. H.; Sondermann, H. Science 2010, 327, 866. 
35 Hickman, J. W.; Harwood, C. S. Mol. Microbiol. 2008, 69, 376. 
36 Sudarsan, N.; Lee, E. R.; Weinberg, Z.; Moy, R. H.; Kim, J. N.; Link, K. H.; 
Breaker, R. R. Science 2008, 321, 411. 
37 Lee, E. R.; Baker, J. L.; Weinberg, Z.; Sudarsan, N.; Breaker, R. R. Science 
2010, 329, 845. 
38 Yan, H.; Chen, W. Chem. Soc. Rev. 2010, 39. 
39 Ausmees, N.; Mayer, R.; Weinhouse, H.; Volman, G.; Amikam, D.; 
Benziman, M.; Lindberg, M. FEMS Microbiol. Lett. 2001, 204, 163. 
40 Paul, R.; Weiser, S.; Amiot, N. C.; Chan, C.; Schirmer, T.; Giese, B.; Jenal, U. 
Genes Dev. 2004, 18, 715. 
41 Paul, R.; Abel, S.; Wassmann, P.; Beck, A.; Heerklotz, H.; Jenal, U. J. Biol. 
Chem. 2007, 282, 29170. 
42 Hunter, J. L.; Severin, G. B.; Koestler, B. J.; Waters, C. M. BMC Microbiol. 
2014, 14, 22. 
43 Christen, B.; Christen, M.; Paul, R.; Schmid, F.; Folcher, M.; Jenoe, P.; 
Meuwly, M.; Jenal, U. J. Biol. Chem. 2006, 281, 32015. 
44 Navarro, M. V.; De, N.; Bae, N.; Wang, Q.; Sondermann, H. Structure 2009, 
17, 1104. 
45 Chan, C.; Paul, R.; Samoray, D.; Amiot, N. C.; Giese, B.; Jenal, U.; Schirmer, 
T. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 17084. 
46 Ryjenkov, D. A.; Tarutina, M.; Moskvin, O. V.; Gomelsky, M. J. Bacteriol. 
2005, 187, 1792. 
47 Yang, C. Y.; Chin, K. H.; Chuah, M. L.; Liang, Z. X.; Wang, A. H.; Chou, S. 
H. Acta Crystallogr. D Biol. Crystallogr. 2011, 67, 997. 
48 De, N.; Pirruccello, M.; Krasteva, P. V.; Bae, N.; Raghavan, R. V.; 
Sondermann, H. PLoS Biol. 2008, 6, e67. 
49 Schmidt, A. J.; Ryjenkov, D. A.; Gomelsky, M. J. Bacteriol. 2005, 187, 4774. 





51 Ryan, R. P.; Fouhy, Y.; Lucey, J. F.; Crossman, L. C.; Spiro, S.; He, Y. W.; 
Zhang, L. H.; Heeb, S.; Camara, M.; Williams, P.; Dow, J. M. Proc. Natl. 
Acad. Sci. U. S. A.  2006, 103, 6712. 
52 Bellini, D.; Caly, D. L.; McCarthy, Y.; Bumann, M.; An, S. Q.; Dow, J. M.; 
Ryan, R. P.; Walsh, M. A. Mol. Microbiol. 2014, 91, 26. 
53 Barends, T. R.; Hartmann, E.; Griese, J. J.; Beitlich, T.; Kirienko, N. V.; 
Ryjenkov, D. A.; Reinstein, J.; Shoeman, R. L.; Gomelsky, M.; Schlichting, I. 
Nature 2009, 459, 1015. 
54 Minasov, G.; Padavattan, S.; Shuvalova, L.; Brunzelle, J. S.; Miller, D. J.; 
Baslé, A.; Massa, C.; Collart, F. R.; Schirmer, T.; Anderson, W. F. J. Biol. 
Chem. 2009, 284, 13174. 
55 Christen, M.; Christen, B.; Folcher, M.; Schauerte, A.; Jenal, U. J. Biol. 
Chem. 2005, 280, 30829. 
56 Salter, E. A.; Wierzbicki, A. J. Phys. Chem. B 2007, 111, 4547. 
57 Tamayo, R.; Tischler, A. D.; Camilli, A. J. Biol. Chem. 2005, 280, 33324. 
58 Tchigvintsev, A.; Xu, X.; Singer, A.; Chang, C.; Brown, G.; Proudfoot, M.; 
Cui, H.; Flick, R.; Anderson, W. F.; Joachimiak, A.; Galperin, M. Y.; 
Savchenko, A.; Yakunin, A. F. J. Mol. Biol. 2010, 402, 524. 
59 Sundriyal, A.; Massa, C.; Samoray, D.; Zehender, F.; Sharpe, T.; Jenal, U.; 
Schirmer, T. J. Biol. Chem. 2014. 
60 Lovering, A. L.; Capeness, M. J.; Lambert, C.; Hobley, L.; Sockett, R. E. 
mBio 2011, 2. 
61 Wigren, E.; Liang, Z. X.; Römling, U. Mol. Microbiol. 2014, 91, 1. 
62 Lindenberg, S.; Klauck, G.; Pesavento, C.; Klauck, E.; Hengge, R. EMBO J. 
2013, 32, 2001. 
63 Hengge, R. Nat. Rev. Micro. 2009, 7, 263. 
64 Römling, U.; Galperin, M. Y.; Gomelsky, M. Microbiol. Mol. Biol. Rev. 2013, 
77, 1. 
65 Ryjenkov, D. A.; Simm, R.; Römling, U.; Gomelsky, M. J. Biol. Chem. 2006, 
281, 30310. 
66 Amikam, D.; Galperin, M. Y. Bioinformatics 2006, 22, 3. 
67 Duerig, A.; Abel, S.; Folcher, M.; Nicollier, M.; Schwede, T.; Amiot, N.; 
Giese, B.; Jenal, U. Genes Dev. 2009, 23, 93. 
68 Petters, T.; Zhang, X.; Nesper, J.; Treuner-Lange, A.; Gomez-Santos, N.; 
Hoppert, M.; Jenal, U.; Søgaard-Andersen, L. Mol. Microbiol. 2012, 84, 147. 
69 Newell, P. D.; Monds, R. D.; O'Toole, G. A. Proc. Natl. Acad. Sci. U. S. A. 
2009, 106, 3461. 
70 Rakshe, S.; Leff, M.; Spormann, A. M. Appl. Environ. Microbiol. 2011, 77, 
2196. 
71 Yang, F.; Tian, F.; Li, X.; Fan, S.; Chen, H.; Wu, M.; Yang, C. H.; He, C. 
Mol. Plant Microbe. Interact. 2014, DOI: 10.1094/MPMI-12-13-0371-R. 
72 Chin, K. H.; Lee, Y. C.; Tu, Z. L.; Chen, C. H.; Tseng, Y. H.; Yang, J. M.; 
Ryan, R. P.; McCarthy, Y.; Dow, J. M.; Wang, A. H.; Chou, S. H. J. Mol. 
Biol. 2010, 396, 646. 




74 Wilksch, J. J.; Yang, J.; Clements, A.; Gabbe, J. L.; Short, K. R.; Cao, H.; 
Cavaliere, R.; James, C. E.; Whitchurch, C. B.; Schembri, M. A.; Chuah, M. 
L.; Liang, Z. X.; Wijburg, O. L.; Jenney, A. W.; Lithgow, T.; Strugnell, R. A. 
PLoS Pathog. 2011, 7, e1002204. 
75 Ko, J.; Ryu, K. S.; Kim, H.; Shin, J. S.; Lee, J. O.; Cheong, C.; Choi, B. S. J. 
Mol. Biol. 2010, 398, 97. 
76 Benach, J.; Swaminathan, S. S.; Tamayo, R.; Handelman, S. K.; Folta-
Stogniew, E.; Ramos, J. E.; Forouhar, F.; Neely, H.; Seetharaman, J.; Camilli, 
A.; Hunt, J. F. EMBO J. 2007, 26, 5153. 
77 Habazettl, J.; Allan, M. G.; Jenal, U.; Grzesiek, S. J. Biol. Chem. 2011, 286, 
14304. 
78 Baraquet, C.; Murakami, K.; Parsek, M. R.; Harwood, C. S. Nucleic Acids 
Res. 2012. 
79 Baraquet, C.; Harwood, C. S. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 
18478. 
80 Smith, K. D.; Lipchock, S. V.; Ames, T. D.; Wang, J.; Breaker, R. R.; Strobel, 
S. A. Nat. Struct. Mol. Biol. 2009, 16, 1218. 
81 Shanahan, C. A.; Strobel, S. A. Org. Biomol. Chem. 2012, 10, 9113. 
82 Nakayama, S.; Roelofs, K.; Lee, V. T.; Sintim, H. O. Mol. Biosyst. 2012, 8, 
726. 
83 Travascio, P.; Li, Y.; Sen, D. Chem. Biol. 1998, 5, 505. 
84 Roembke, B. T.; Nakayama, S.; Sintim, H. O. Methods 2013, 64, 185. 
85 Roembke, B.; Wang, J.; Nakayama, S.; Zhou, J.; Sintim, H. RSC Advances 
2013, 3, 6305. 
86 Nakayama, S.; Luo, Y.; Zhou, J.; Dayie, T. K.; Sintim, H. O. Chem. Commun. 
(Camb) 2012, 48, 9059. 
87 Lieberman, O. J.; Orr, M. W.; Wang, Y.; Lee, V. T. ACS Chem. Biol. 2014, 9, 
183. 
88 Ohana, P.; Delmer, D.; Volman, G.; Benziman, M. Plant Cell Physiol. 1998, 
39, 153. 
89 Ohana, P.; Delmer, D. P.; Carlson, R. W.; Glushka, J.; Azadi, P.; Bacic, T.; 
Benziman, M. Plant Cell Physiol. 1998, 39, 144. 
90 Sambanthamoorthy, K.; Sloup, R. E.; Parashar, V.; Smith, J. M.; Kim, E. E.; 
Semmelhack, M. F.; Neiditch, M. B.; Waters, C. M. Antimicrob. Agents 
Chemother. 2012, 56, 5202. 
91 Sambanthamoorthy, K.; Luo, C.; Pattabiraman, N.; Feng, X.; Koestler, B.; 
Waters, C. M.; Palys, T. J. Biofouling 2014, 30, 17. 
92 Antoniani, D.; Bocci, P.; Maciag, A.; Raffaelli, N.; Landini, P. Appl 
Microbiol. Biotechnol. 2010, 85, 1095. 
93 Antoniani, D.; Rossi, E.; Rinaldo, S.; Bocci, P.; Lolicato, M.; Paiardini, A.; 
Raffaelli, N.; Cutruzzolà, F.; Landini, P. Appl. Microbiol. Biotechnol. 2013, 
97, 7325. 
94 Schewe, T. Gen. Pharmacol. 1995, 26, 1153. 
95 Zhang, Z.; Gaffney, B. L.; Jones, R. A. J. Am. Chem. Soc. 2004, 126, 16700. 
 96 Zhang, Z.; Kim, S.; Gaffney, B. L.; Jones, R. A. J. Am. Chem. Soc. 




97 Gentner, M.; Allan, M. G.; Zaehringer, F.; Schirmer, T.; Grzesiek, S. J. Am. 
Chem. Soc. 2012, 134, 1019. 
98 Kelsey, I.; Nakayama, S.; Sintim, H. O. Bioorg. Med. Chem. Lett. 2012, 22, 
881. 
99 Witte, G.; Hartung, S.; Büttner, K.; Hopfner, K. P. Mol. Cell. 2008, 30, 167. 
100 Corrigan, R. M.; Abbott, J. C.; Burhenne, H.; Kaever, V.; Gründling, A. PLoS 
Pathog. 2011, 7, e1002217. 
101 Mehne, F. M.; Gunka, K.; Eilers, H.; Herzberg, C.; Kaever, V.; Stülke, J. J. 
Biol. Chem. 2013, 288, 2004. 
102 Luo, Y.; Helmann, J. D. Mol. Microbiol. 2012, 83, 623. 
103 Witte, C. E.; Whiteley, A. T.; Burke, T. P.; Sauer, J. D.; Portnoy, D. A.; 
Woodward, J. J. mBio 2013, 4, e00282. 
104 Gomelsky, M. Mol. Microbiol. 2011, 79, 562. 
105 Zhou, J.; Sayre, D. A.; Zheng, Y.; Szmacinski, H.; Sintim, H. O. Anal. Chem. 










Chapter 2. Potent suppression of c-di-GMP synthesis via 
I-site allosteric inhibition of diguanylate cyclases with 2‟-F-c-
di-GMP 
(This chapter was published in Zhou et al. Bioorg. Med. Chem. 2013, 21, 4396) 
2.1 2’-modified analogs of c-di-GMP 
2.1.1 Introduction 
Cyclic diguanylic monophosphate, c-di-GMP, was discovered in the late 80s as an 
allosteric modulator of cellulose synthase in bacteria,
1
 but it was not until almost two 
decades later that c-di-GMP was established as a second messenger and its central 
role in biofilm formation and the regulation of virulence-related factors in diverse 
bacteria was discovered.
2-7
 C-di-GMP is produced from two guanosine triphosphate 
(GTP) molecules by diguanylate cyclases (DGCs), and is further broken down into 
5‟-phosphoguanylyl-(3‟-5‟)-guanosine (pGpG) by specific phosphodiesterases 
(PDEs).
8-11 
Generally, increased concentration of c-di-GMP in most bacteria leads to 
increased biofilm formation.
12-14 
Most DGCs that synthesize c-di-GMP have an 
inhibitory site (I-site), where c-di-GMP binds and allosterically inhibits product 
formation.
9,15 
Small molecules that can bind to the I-site of DGCs to inhibit c-di-GMP 
synthesis could potentially modulate biofilm formation and virulence factor 
production in a variety of bacteria. The identification of the structural features on c-
di-GMP that confer specific binding to DGCs as well as other c-di-GMP binding 




like molecules that could be used to perturb bacterial physiology. Thus far, the 
majority of c-di-GMP analogs synthesized have been tested for binding to 
riboswitches
16,17





have been tested for binding to proteins. Analyses of the crystal structures of over 20 
c-di-GMP binding proteins reveal that the majority of these proteins make numerous 
contacts (via hydrogen bonding, π-π stacking or salt bridges) with the phosphate and 
guanine nucleobase of c-di-GMP. It is therefore not surprising that the analogs tested 
to date have displayed reduced affinity for c-di-GMP effector proteins.
18-20
 On the 
other hand, analyses of over 20 c-di-GMP binding proteins revealed that some 
proteins have H-bonding interactions between the 2‟-OH moiety of c-di-GMP and 
protein residues whereas in other proteins no polar interactions between the 2‟-OH of 
c-di-GMP and protein residues were seen. Additionally, in some proteins one or both 
of the 2‟-OH groups were either fully or partially buried inside the protein whereas 
for others, this moiety was solvent exposed. We therefore rationalized that the 2‟-
position of c-di-GMP is a prime position to modify in order to prepare ligands that 
could selectively bind to some c-di-GMP binding proteins and not others. In this 
paper, we investigated the modification of the 2‟-position of c-di-GMP with 
hydrogen, fluorine or methoxy groups (see Figure 2.1). The replacement of the 
hydroxyl group at the 2‟-position in riboses not only eliminates the potential for both 
H-bonding donation or acceptance but could also affect the sugar puckering of the 
ribose, which could affect the relative orientation of the guanine bases of c-di-GMP 
and possibly affect binding interactions that are remote from the 2‟-OH site. Both 




however the methoxy substitution adds steric hindrance. Although fluorine is a good 
isostere of the OH group, it cannot act as a H-bond donor. Hence 2‟-F-c-di-GMP 
could be used to tease out the importance of hydrogen bonding donation at the 2‟-
position of c-di-GMP. Interestingly, we have discovered that the replacement of the 
2‟-OH of c-di-GMP with fluorine affords an analog that binds to several c-di-GMP-
binding proteins with similar or even better affinity than c-di-GMP. We recently 
revealed that small changes to the phosphodiester backbone of c-di-GMP (2.1) give 
endo-S-c-di-GMP remarkably decreased propensity to form G-quadruplexes and to 
bind c-di-GMP receptors.
18 
In order to determine the structural features of c-di-GMP 
that are important for polymorphism and binding to effector proteins, we prepared 
and studied 2‟-modified analogs of c-di-GMP (2‟-F-c-di-GMP (2.2) and 2‟-H-c-di-





Figure 2.1 2‟-modified analogs of c-di-GMP designed and synthesized. 
2.1.2 Synthesis of c-di-GMP analogs 
 
Scheme 2.1 Synthesis of compounds 2.2 and 2.3 via solution phase synthesis. 
Modified conditions of reported synthesis
22 
were used: (a) pyridinium 
trifluoroacetate, H2O, then t-BuNH2. (b) dichloroacetic acid, then quenched with 
pyridine. (c) compound 2.5 or 2.6. (d) t-BuOOH. (e) dichloroacetic acid, then 








Scheme 2.2 Solid-phase synthesis strategy of c-di-GMP and/or analogs. 
The facile solid-phase synthesis of c-di-GMP or analogs have been reported by 
Sintim and co-workers.
21
 (Scheme 2.2) The general synthesis strategy used 
sulfonylethyl-ODMT CPG coupling with two different phosphoramidites (P-
methoxyphosphoramidite and cyanoethyl phosphate protected phosphoramidite).
21
 
Cyclization was carried out by using 0.1 M 1-mesitylenesulfonyl-3-nitro-1, 2, 4-
triazole (MSNT) in pyridine, followed by the selective deprotection on the phosphate 




using a modified version of solution phase synthesis (Scheme 2.1) due to the need for 
larger quantities of these c-di-GMP analogs. Jones recently disclosed a simple 
synthesis of c-di-GMP in one flask without any purification of the intermediates.
22
 In 
our hands however, we have observed that purification of the protected cyclic 
dinucleotide (compound 2.11 or 2.12, Scheme 2.1) before the global deprotection 
step made the purification of the final product significantly easier (see Figure 2.2 for 





Figure 2.2 HPLC chromatography of c-di-GMP analogs (2.2 and 2.3). HPLC 
conditions: Nacalai Tesque Cosmosil
®






with 1 13 % B at 0  17 min (A: 100 mM triethylammonium acetate (TEAA) in 
water; B: acetonitrile, pH 7.0), rt with a UV detector.  
 
The aggregative behavior of c-di-GMP has already been characterized using both CD 
and NMR.
18,23-27
 At low micromolar concentrations (below 100 µM), it is known that 
c-di-GMP exists as monomeric and dimeric forms. The monomeric and dimeric forms 





Schirmer and co-workers have shown that at low concentrations (such as 10 µM), c-
di-GMP is predominantly monomeric.
27
 On the other hand, at higher concentrations 
(such as 400 µM), c-di-GMP forms G-quadruplexes (predominantly octameric) in the 






HNMR spectra revealed that compounds 2.2 and 2.3 exist as MD (MD stands for 
monomeric/dimeric forms in fast equilibrium, see reference 27) at 30 °C without 
added K
+
 (see Figure 2.3c and 2.4c). For 2‟-F-c-di-GMP (Figure 2.3c), the singlet 
peak at 7.98 ppm was assigned to the guanine H8 and a doublet at 6.11ppm was 
assigned to the anomeric H1‟. Upon adding 100 mM K+ to the 2‟-F-c-di-GMP 
solution (Figure 2.3b), more peaks appeared near 7.95 ppm and 6.07 ppm. These new 
peaks correspond to the octameric form (labeled as O) of 2‟-F-c-di-GMP, which form 
when potassium is present, vide infra. Upon heating the sample to 60 
o
C (which will 
break all aggregates, Figure 2.3a), the multiple peaks disappeared and new peaks 
appeared at 8.28 and 6.40 ppm. For the MD form of 2‟-H-c-di-GMP (Figure 2.3c), a 




6.31 and 6.29 ppm were assigned to the anomeric H1‟ proton. Upon adding 100 mM 
K+ to the 2‟-H-c-di-GMP solution (Figure 2.4b), more peaks appeared near 8.05 
ppm and 6.30 ppm, due to the formation of different aggregates of 2‟-H-c-di-GMP. 
We characterized the aggregates following literature precedents.
24
 We used diffusion 
ordered spectroscopy (DOSY) experiments, followed by T1/T2 relaxation analysis of 
the diffusion constants to obtain the diffusion constants of the MD, tetrameric (T) and 
octameric (O) forms of c-di-GMP and its analog.
18
 The diffusion constant, D, can be 
calculated using the Stokes-Einstein equation, D = k T / (6 π η R), where k is the 
Boltzmann constant, T is the temperature, η is the solvent viscosity and R is the 







HNMR stacked spectra of 3.0 mM analog 2.2 in D2O. Conditions: (a) 3.0 
mM 2‟-F-c-di-GMP, 100 mM KCl 60 
o
C. (b) 3.0 mM 2‟-F-c-di-GMP, 100 mM KCl, 
30 
o
C. (c) 3.0 mM 2‟-F-c-di-GMP, no metal cation, 30 
o
C. (d) 3.0 mM 2‟-F-c-di-







HNMR stacked spectra of 3.0 mM analog 2.3 in D2O. Conditions: (a) 3.0 
mM 2‟-H-c-di-GMP, 100 mM KCl 60 
o
C. (b) 3.0 mM 2‟-H-c-di-GMP, 100 mM KCl, 
30 
o
C. (c) 3.0 mM 2‟-H-c-di-GMP, no metal cation, 30 
o
C. (d) 3.0 mM 2‟-H-c-di-
GMP, T1/T2 relaxation analysis (from DOSY experiments). 
 
The diffusion constants of 2‟-F-c-di-GMP and 2‟-H-c-di-GMP in their MD form 
could be obtained by DOSY experiments using the samples that did not contain 
potassium. According to Grzesiek el al.
27




mM, MD is made up of approximately 80-90% monomeric form so the diffusion 
constant obtained for the MD peak could be approximated for the monomeric form. 
From the Stokes-Einstein equation, the diffusion constants for tetrameric (T) and 
octameric (O) forms of 2‟-F-c-di-GMP and 2‟-H-c-di-GMP were calculated following 
precedent,
24
 using calculated radii for these complexes (see Table 2.1).  
 
For both 2‟-H and 2‟-F-c-di-GMP in the presence of K
+
, the main species that existed 









/s for the 
octameric (O) form of 2‟-F-c-di-GMP G-quadruplexes were obtained. For 2‟-H-c-di-
GMP in the presence of K
+




/s and an 




/s for the octameric form were obtained. These 
aggregation studies indicate that substitution of the 2‟-position of c-di-GMP does not 









Table 2.1 Calculations of the radii of c-di-GMP and analogs (2.2 and 2.3) in their 















Monomeric (cis) 6.37 C2 3.81 (average measured value)
a
 
Monomeric (tran) 6.16 C2 -- 
Dimeric  8.01 -- 3.03 
Tetrameric  10.03 D4 2.42 
Octameric  11.96 D4 2.03 
2‟-H-c-di-GMP  
Monomeric (cis) 6.19 C2 3.66 (average measured)
a
 
Monomeric (tran) 6.16 C2 -- 
Dimeric  7.74 -- 2.92 
Tetrameric  9.78 D4 2.31 
Octameric  11.92 D4 1.90 
a
The diffusion constants of monomeric form of 2‟-F-c-di-GMP and 2‟-H-c-di-GMP 








2.2 Effect of 2’-modification on binding to proteins  
2.2.1 Theoretical analysis of c-di-GMP binding proteins 
We analyzed 20 c-di-GMP binding proteins in the PDB databank for H-bonding 
interactions between the protein residues and the 2‟-OH of c-di-GMP.
28





) and two PilZ domain proteins
28n,o
) of the 20 proteins 
analyzed (30%) utilized H-bonding interactions between protein residues and the 2‟-
OH moiety of c-di-GMP for recognition (see Figure 2.5a-c).  
 
Figure 2.5 C-di-GMP is shown in sticks and colored by atom (oxygen in red, 
nitrogen in blue, carbon in green and phosphorus in orange); amino acid residues are 
shown in blue sticks. a) dimeric c-di-GMP bound to WspR (DGC domain; PDB code 
3I5C). b) Monomeric c-di-GMP bound to LapD (EAL domain; PDB code 3PJT). c) 
Dimeric c-di-GMP bound to PP4397 (PilZdomain; PDB code 3KYF). d) Monomeric 





2.2.2 IC50s against c-di-GMP binding proteins and analogs 
The effect of the 2‟-OH substitution on biological activity was interrogated by testing 
the ability of each analog to compete for 
32
P-c-di-GMP binding to the diguanylate 
cyclase WspR
9,29
, the phosphodiesterase RocR
30,31
 and the PilZ domain-containing 
Alg44
32,33
. As a positive control, unlabeled c-di-GMP was used as a competitor. The 
IC50 of c-di-GMP for WspR, RocR and Alg44 was 48.9 µM, 21 nM and 7.7 µM, 
respectively (Table 2.2). 2‟-H-c-di-GMP (2.3) was able to compete for binding to 
RocR with an IC50 of 25 nM and to Alg44 with an IC50 of 13.4 µM, but it was unable 
to compete for binding to WspR with an IC50 greater than 100 µM (Table 2.2). 2‟-F-
c-di-GMP (2) was able to compete for binding to WspR, RocR and Alg44 with an 
IC50 of 11 µM , 723 nM and 3.1 µM, respectively (Table 2.2). The binding profile of 
2‟-F-c-di-GMP is interesting because it appears to bind to the I-site of WspR tighter 
(4 times) than c-di-GMP, whereas for RocR, c-di-GMP binds tighter (~35 times) than 
2‟-F-c-di-GMP. The crystal structure of WspR in complex with c-di-GMP (see 
Figure 2.5a) reveals that residue R194 contacts c-di-GMP via H-bonding. If the 2‟-F 
modification of c-di-GMP does not grossly affect the sugar puckering (see Table 
2.3), then one could assume that the fluorine isostere allows for fluorine-hydrogen 
bonding interactions between 2‟-F and arginine in the I-site.
34,35 
Most c-di-GMP 
binding proteins utilize arginine patches to recognize c-di-GMP. It is assumed that the 
arginine residues are critical for salt bridge interactions with the phosphate groups as 
well as both Hoogsteen hydrogen bonding interactions and cation-nucelobase 
interactions. Herein, we provide data that suggests that arginine-2‟-OH interactions 




(three out of ten DGCs analyzed
28a-h
 displayed H-bonding interactions between 
protein residue and 2‟-OH). Future structural studies using c-di-GMP analogs and 
various DGCs should help shed more light on the role 2‟-OH on I-site binding. 
 
Table 2.2 IC50 value against protein (WspR, RocR and Alg44) by c-di-GMP and 
analogs (2.1 to 2.4). 
 IC50 (μM) 
WspR RocR Alg44 
c-di-GMP  48.91 0.02 7.69 
2‟-F-c-di-GMP  11.01 0.72 3.12 
2‟-H-c-di-GMP  >100 0.02 13.36 
2‟-OMe-c-di-GMP  >100 3.14 >100 
 
 
As already mentioned, 2‟-F-c-di-GMP binds to RocR worse than c-di-GMP. 
Although the crystal structure of RocR (an EAL-domain protein) R286W nutant 
protein has been solved, the structure did not contain the c-di-GMP ligand.
36 
We 
however note that some EAL-containing proteins, such as LapD, display extensive 
interactions between polar residues and c-di-GMP (see Figure 2.5b). The 2‟-deoxy 
analog of c-di-GMP (2‟-H-c-di-GMP), however, binds to RocR as well as c-di-GMP 
does (see Table 2.2). Therefore we do not believe that the reduction in polar 
interactions between RocR residues and the 2‟-position of c-di-GMP accounts for the 
reduced binding of 2‟-F-c-di-GMP to RocR. It must be noted that the modification of 
the 2‟-position of nucleic acids not only affects the sugar puckering and/or H-bonding 




and hence the orientation of the nucleobase (see Table 2.3 for computed dihedral 
angles). The replacement of the 2‟-OH with 2‟-OMe can be considered conservative 
for the purposes of H-bonding interactions and sugar puckering (both groups can 
accept hydrogen bonds from arginines and both substitutions lead to 3’-endo, 2’-exo 
puckering modes).
37,38 
The 2‟-OMe moiety is, however, more sterically encumbered, 
and so for proteins whereby there is little room to spare in the binding pocket, 
especially around the region surounding the 2‟-position of c-di-GMP, it is expected 
that 2‟-OMe analog of c-di-GMP would bind poorly. 2‟-OMe-c-di-GMP was the 
worst competitor with 
32
P-c-di-GMP for binding to all tested proteins with an IC50 
greater than 100 µM for WspR and Alg44, and with an IC50 of 3.14 µM for RocR 
(compare IC50 of 20 nM for c-di-GMP competing with 
32
P-c-di-GMP for RocR 
binding). This means that c-di-GMP binds to RocR at least two orders of magnitude 
tighter than 2‟-OMe-c-di-GMP does. The sensitivity of WspR towards 2‟-
modification of c-di-GMP is surprising because the bound c-di-GMP in WspR is 
mostly solvent exposed (see Figure 2.4a). We have earlier observed that WspR is 
also sensitive to phosphate modification of c-di-GMP
18
 and so it appears that this 










constant JH1', H2'  (Hz)  
from NMR 










c-di-GMP  2.2 3'-endo, 2'-exo 104.0 
2‟-F-c-di-GMP  1.1 3'-endo, 2'-exo 88.4 
2‟-H-c-di-GMP  






2.2.3 2’-F-c-di-GMP is a potent inhibitor of c-di-GMP synthase WspR 
Since 2‟-F-c-di-GMP competes with the 
32
P-labeled c-di-GMP for binding to both 
WspR and RocR, we asked whether the compound affected the enzymatic activity of 
these enzymes and additional enzymes PA1107
40
 (DGC) and PvrR
41
 (PDE). In the 
absence of competitor or with cGMP, WspR and PA1107 were active and converted 
GTP to c-di-GMP (see Figure 2.6a and 2.6b). In the presence of c-di-GMP, the 
activity of both WspR and PA1107 were reduced. 2‟-F-c-di-GMP, which binds better 
to WspR than c-di-GMP (see Table 2.2), caused a greater inhibition of the 




c-di-GMP occupies the I-site and acts to inhibit the activity of WspR and PA1107. 
RocR and PvrR phosphodiesterases were able to convert c-di-GMP to pGpG in the 
absence of competitor or with cGMP. However in the presence of c-di-GMP and 2‟-
F-c-di-GMP, the activity of RocR (but not PvrR) was inhibited (see Figure 2.6c and 
2.6d).  
 
Figure 2.6 a) and b) Inhibition of c-di-GMP synthesis by WspR and PA1107 with 
guanine-containing nucleotides. c) and d) Inhibition of c-di-GMP hydrolysis by RocR 
and PvrR with guanine-containing nucleotides. Measurements were done in triplicate. 
 
The ability of 2‟-F-c-di-GMP to alter WspR activity was further interrogated by 
determining the effect of the inhibitor on Vmax and Km for each enzyme. For WspR, 




determined by performing time course assays at the indicated GTP substrate 
concentrations. Increasing either c-di-GMP or 2‟-F-c-di-GMP led to a decrease of 
both the Vmax and the Km, indicating that binding at the I-site leads to allosteric 
inhibition of the diguanylate cyclase activity (Figure 2.7 and Table 2.4). 
 
Figure 2.7 Inhibition of c-di-GMP synthesis by different concentrations of c-di-GMP 









Table 2.4 Effect of c-di-GMP and 2‟-F-c-di-GMP on WspR enzyme kinetics. 
Inhibitors Concentration (µM) Vmax (µmole/min) Km
app
 (µM) 
None 0 13.9  1.2 29.8  7.9 
c-di-GMP 
10 8.5  0.4 19.7  3.7 
30 2.3  0.3 8.3  6.1 
100 0.5  0.1 7.2  10.8 
2‟-F-c-di-GMP 
10 11.3  1.5 31.7  13.3 
30 2.8  0.3 17.7  7.8 
























In the last decade, there have been intensive efforts to control bacterial virulence and 
biofilm formation with small molecules.
42-50 
C-di-GMP has emerged as a master 
regulator of bacterial biofilm formation and small molecules that could perturb c-di-
GMP signaling could have anti-biofilm properties. C-di-GMP signaling in bacteria is 
intricate and involves myriads of metabolism and effector proteins and RNAs. In 
order to perturb this signaling, with a view of disrupting bacterial biofilm formation, 
one could use a small molecule to either inhibit c-di-GMP synthesis or compete with 
c-di-GMP binding to effector molecules. This work reveals that different effector 
molecules (or receptors of c-di-GMP) are differentially sensitive to c-di-GMP 
modification and suggests that these proteins might be using different strategies to 
recognize c-di-GMP. As it would be challenging to find one small molecule that 
could simultaneously inhibit many classes of c-di-GMP effector proteins and RNAs, 
each with different binding pockets, it appears that the most effective strategy to 
inhibit c-di-GMP signaling is to either inhibit synthesis by DGC or to “quench” the 
signaling molecule itself via small molecule-induced aggregation.
51
 The discovery 
that 2‟-F-c-di-GMP is a potent suppressor of c-di-GMP synthesis lays the foundation 
for the preparation of cell permeable analogs of 2‟-F-c-di-GMP, which could be used 
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Chapter 3. Binding studies between c-di-GMP analogs and c-di-
GMP riboswitch 
(This chapter was published in Zhou et al. Molecules 2012, 17, 13376) 
3.1 Synthesis and polymorphism of endo-S-c-di-GMP analogs  
3.1.1 Introduction 









 and RNA riboswitches
11,12
. Small 
molecules that could compete with c-di-GMP for binding to receptors have the 
potential to inhibit biofilm formation and virulence factors production in bacteria. 
There are several precedents whereby the modifications of natural nucleotides have 
produced analogs with interesting biological profiles and some of these analogs could 
even have clinical utility.
13-21
 Previously, we showed that a conservative change to 
one of the phosphodiester “bridging” oxygens in c-di-GMP gave an analog called 
endo-S-c-di-GMP (3.2), see Figure 3.1, which has a much lower propensity to form 
aggregates compared to c-di-GMP.
22
 Importantly, endo-S-c-di-GMP could compete 
with the natural c-di-GMP for binding to RocR, a PDE, but had little affinity for 
WspR (a DGC) or Alg44 (a PilZ-containing protein). This suggests that modifications 
to the phosphate moiety of c-di-GMP, at the bridging oxygen position at the 
phosphodiester moiety could give analogs of c-di-GMP, which could be used to 





Figure 3.1 Family of dual-modified c-di-GMP analogs (endo-S-c-di-GMP analogs) 
synthesized. 
 
Recent reports suggest that the 2‟-modification of c-di-GMP differentially affected 
binding of these analogs to c-di-GMP riboswitches.
12,23-26
 We wondered if the 
simultaneous modification of both the phosphate, at the bridging oxygen position of 
the phosphodiester moiety, and the 2‟-position would lead to another series of c-di-
GMP analogs with differential binding profiles. Herein, we describe the synthesis, 
biophysical characterization and binding to Vc2 RNA of this new class of c-di-GMP 
analogs (called endo-S-c-di-GMP analogs), see Figure 3.1 for structures. 
3.1.2 Synthesis of endo-S-c-di-GMP analogs 
Endo-S-c-di-GMP analogs (3.3 to 3.5) were facilely synthesized on a solid support,
27
 
following the strategy outlined in Scheme 3.1. Briefly, a guanosine phosphoramidite 
was coupled to a phosphate CPG and the first nucleotide was sulfurized using 




the same guanosine phosphoramidite, but this time iodine was used for the oxidation 
step to give an interlinking phosphate. The DMT group was then deprotected, using 
trichloroacetic acid and the 5‟-hydroxyl group was converted into an iodide. The 
dinucleotide was then cleaved from the solid support with NH4OH (30% in water). 
This step also cleaved the cyanoethyl protecting group on the phosphate as well as the 
acetyl group on the exocyclic amine of the guanine. Upon cleavage from the solid 
support, a cyclization ensued via a SN2 displacement of the 5‟-iodide with the 3‟-





Scheme 3.1 Synthesis of endo-S-c-di-GMP analogs (3.3 to 3.5). Reagents and 
conditions: a) programmed DNA synthesizer; b) methyltriphenoxyphosphonium 
iodide, 2,6-lutidine, anhydrous DMF, rt, 1h; c) 30% NH4OH, 40 °C, 12h. 
 
3.1.3 Polymorphism of endo-S-c-di-GMP analogs 
The equilibrium of different polymorphic states of c-di-GMP, dictated by the 
physiological condition of the bacterial cells, is highly relevant to the bacterial 
virulence and mobility. Given the flexibility of the c-di-GMP macrocycle, different 
sugar packer modes of the nucleosides, the rotation of the glycosidic bonds and the 
intercalation of the two guanosine moieties, it is expected that c-di-GMP and its 




conformation for each c-di-GMP molecule in physiological condition depends on 
various factors, including the ion intensity, c-di-GMP concentration and the receptor 
protein or RNA that it interacts with. The crystal structures of c-di-GMP/protein or c-
di-GMP/RNA complexes show that c-di-GMP can bind to different receptors using in 
different conformational modes. For example, c-di-GMP binds to most I-sites of 
DGCs as a self intercalated dimer
1
 whereas for PDEs and some PilZ proteins, c-di-
GMP binds to the active site as a monomer in either the open form (whereby the two 
guanines are relatively far away to each other)
4
 or the closed form (whereby the two 
guanines are relatively closed to each other).
7
 Recently Chou et al. further observed 
that different proteins could bind to different conformers (with different glycosidic 
bond angles and/or the sugar pucker modes) of the open form of c-di-GMP.
28
 Thus it 
is possible to selectively target c-di-GMP receptors with c-di-GMP-like molecules 
that mainly exist in a particular conformation, which nicely fits into the binding site 
of an effector protein or RNA.  
 
C-di-GMP (3.1) at millimolar concentrations and in the presence of potassium cations 
also forms several polymorphs of aggregates, including dimers, tetramers and 
octamers (which contain G-tetrads).
22,29,30
 Interestingly, by replacing one of the 
bridging oxygens of the phosphodiester units in c-di-GMP with a sulfur atom (a 
conservative modification) to give an analog that we name endo-S-c-di-GMP (3.2), 
the propensity to form G-quadruplex drastically diminishes.
22
 We have proposed that 
one could therefore make a gross prediction for the relative propensity of c-di-GMP 




open conformers (where the two guanines are 13.5 Å apart, using distances obtained 
from crystal structures of self-intercalated c-di-GMP complexes) to the closed 
conformer (where the two guanines are 6.8 Å apart).
22
 To simplify the computational 
study, the structures computed in this paper all adopt C2 symmetry, which resemble 
either the closed conformer (anti C3‟-endo) or one of the three open conformers (anti 
C2'-endo) demonstrated in Chou‟s work.
28
 Following our precedent
22
, and using 
Gaussian 09 software
31
 we obtained relative energy differences between the “closed” 
and “open” conformers of c-di-GMP and each analog (3.2 to 3.5), see Table 1. The 
closed conformers of both c-di-GMP (3.1), endo-S-c-di-GMP (3.2) and 2‟-F-endo-S-
c-di-GMP (3.5) seem to be more stable than the open conformers, whereas for 2‟-H-
endo-S-c-di-GMP (3.3) the energies of both conformers are similar. On the other 
hand, the open conformer of 2‟-OMe-endo-S-c-di-GMP (3.4) appears to be more 
stable than the closed conformer. We note however that these calculations are 
simplistic and might not model hydration and salt effects very well, so the obtained 
values have to be interpreted with caution. Nonetheless, the computed data reveals 
that subtle differences at the phosphate and 2‟-position of c-di-GMP could drastically 
affect the conformation of the molecule. Based on our computational study, we 
expected that the conformational preference for 2‟-F-endo-S-c-di-GMP (3.5) would 
be similar to endo-S-c-di-GMP (3.2) whereas 2‟-H-endo-S-c-di-GMP (3.3) and 2‟-
OMe-c-di-GMP (3.4) would behave differently from endo-S-c-di-GMP (3.2) and 
might have a lower propensity to form G-quadruplexes, because the closed 
conformer,which is required for G-quadruplex formation is predicted to be the minor 




When c-di-GMP forms G-quadruplexes, each monomer unit exists in the closed 
conformer.
30
 We wondered if the trend seen in our computational study (Table 3.1) 
would correlate with the aggregative properties of the various endo-S-c-di-GMP 
analogs. We used NMR to characterize the aggregates in the absence or presence of 
potassium. Previously we used DOSY experiment followed by T1/T2 relaxation 
analysis to obtain the diffusion constants of c-di-GMP (3.1) and endo-S-c-di-GMP 
(3.2).
22
 Because an inverse relationship exists between the size of a particle and 
diffusion rate, the T1/T2 relaxation analysis can be used to deduce the size of an 
aggregate, if data for the monomer can be obtained.  
Table 3.1 Computed energy difference between “open” and “closed” forms of c-di-





 ratio (open : closed)
b
 
c-di-GMP  1.9 1:25 
endo-S-c-di-GMP  1.3 1:9 
2‟-H-endo-S-c-di-GMP -0.3 2:1 
2‟-OMe-endo-S-c-di-GMP  -2.2 39:1 
2‟-F-endo-S-c-di-GMP  0.5 1:3 
a
The electronic energy was computed with Gaussian 09 software with HF/6-31G(d) 
basis set. Solvent effect (H2O) was calculated using Onsager‟s model in a self-
consistent reaction field.
b
The ratio was determined from the equilibrium constant K, 





NMR data revealed that 2‟-H-endo-S-c-di-GMP (3.3) and 2‟-OMe-endo-S-c-di-GMP 
(3.4) did not form higher aggregates, even upon the addition of K
+
 (see Figures 3.2b 
and 3.3b), which show that no new peaks appeared when potassium was added to a 
solution containing these two endo-S-c-di-GMP analogs. However, 2‟-F-endo-S-c-di-
GMP (3.5) formed higher aggregates (octamers) in the presence of potassium cations, 
see Figure 3.4. For 2‟-F-endo-S-c-di-GMP, the two singlet sat 8.05 and 7.92 ppm are 
assigned to the two guanine H8 and two sets of doublet at 6.28 and 6.18 ppm are 
assigned to the anomeric H1‟ (see Figure 3.4c). We notice that the line width of the 
2‟-F-endo-S-c-di-GMP peaks at 8.05 and 7.92 ppm are quite broad at 30 
o
C but 
become narrow when potassium is added. Grzesiek and co-workers have shown that 
monomeric c-di-GMP is in equilibrium with dimeric form and it is plausible that the 
line broadening in the absence of potassium is the effect of the dynamic process rising 
from the monomer-dimer exchange.
32
 An alternative explanation could be that the 
line broadening is due to conformational heterogeneity (i.e. introduction of a fluorine 
atom at the 2‟ position changes the C2‟-endo or C3‟-endo equilibrium in the sugar 
ring, and the addition of K
+
 ion changes this equilibrium rate). Upon adding 100 mM 
K
+ 
to a solution containing 2‟-F-endo-S-c-di-GMP (3.5), more peaks appeared near 
8.00 ppm and 6.10 ppm, (see Figure 3.4b), which we interpret as evidence of 
aggregate formation.
22
 Our interpretation is augmented by the fact that heating the 
solution to 60 °C resulted in the disappearance of the additional peaks, meaning that 
the new species that gave rise to the additional peaks contained non-covalent 
interactions. Additionally, DOSY experiments also confirmed that potassium 




ppm, see peaks 1 and 4 on Figure 3.4b) that appeared in the 2‟F-endo-S-c-di-GMP 
1













, whereas the peak at 8.00 ppm and 6.10 ppm(see peaks 2 and 3 













peaks 2 and 3 mainly correspond to monomeric c-di-GMP with calculated radius of 













would correspond to a species of radius 11.60 
Ǻ. This radius corresponds to the calculated radius (11.92 Ǻ) of octameric 2‟F-endo-
S-c-di-GMP and hence provides additional evidence that the addition of potassium to 
2‟F-endo-S-c-di-GMP causes aggregation mainly to octameric forms. 
We have previously shown that endo-S-c-di-GMP (3.2) does not readily form G-
quadruplexes and commented that c-di-GMP G-quadruplex formation is sensitive to 
modifications (even conservative ones). Here we observe that a double modification 
(phosphate to phosphorothioates and 2‟-OH to 2‟-F) can restore the propensity to 
form G-quadruplexes. Conversely, we found that for the other two double 
modifications analyzed in this study (2‟-H and 2‟-OMe from 2‟-OH), there is no 
restoration of the ability to form G-quadruplexes. This suggests that there is 
selectivity of the 2‟ modification in the ability to form G-quadruplexes which is able 







HNMR stacked spectra of 3.0 mM analog 3.3 in D2O. (a) 3.0 mM 2‟-H-
endo-S-c-di-GMP, 100 mM KCl, 60 °C. (b) 3.0 mM 2‟-H-endo-S-c-di-GMP, 100 mM 
KCl, 30 °C. (c) 3.0 mM 2‟-H-endo-S-c-di-GMP, no metal cation, 30 °C. (d) 3.0 mM 
2‟-H-endo-S-c-di-GMP, T1/T2 relaxation analysis (from DOSY experiments). 
 
 
1’ 2’                                                          3’  
1 2                                                        3 
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With K+ at 60 oC
3.2a
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Peak numbers in Figure 3.2b and 3.2c
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Peaks in Figure 3.2c







HNMR stacked spectra of 3.0 mM analog 3.4 in D2O. (a) 3.0 mM 2‟-
OMe-endo-S-c-di-GMP, 100 mM KCl, 60 °C. (b) 3.0 mM 2‟-OMe-endo-S-c-di-
GMP, 100 mM KCl, 30 °C. (c) 3.0 mM 2‟-OMe-endo-S-c-di-GMP, no metal cation, 
30 °C. (d) 3.0 mM 2‟-OMe-endo-S-c-di-GMP, T1/T2 relaxation analysis (from 
DOSY experiments). 
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HNMR stacked spectra of 3.0 mM analog 3.5 in D2O. (a) 3.0 mM 2‟-F-
endo-S-c-di-GMP, 100 mM KCl, 60 °C. (b) 3.0 mM 2‟-F-endo-S-c-di-GMP, 100 mM 
KCl, 30 °C. (c) 3.0 mM 2‟-F-endo-S-c-di-GMP, no metal cation, 30 °C. (d) 3.0 mM 





3.2 Binding Studies between endo-S-c-di-GMP analogs and Class I riboswitch 
One of the motivations for making c-di-GMP analogs is to obtain small molecules 
that could have the potential to disrupt c-di-GMP signaling in bacteria. C-di-GMP has 
been shown to bind to several receptors types (both proteins and RNA).
22-26,33,34
 The 
crystal structures of c-di-GMP bound to both class I and II riboswitches have been 
solved.
35-37
 For class I riboswitch, c-di-GMP is bound in the closed form (see Figure 
3.5). In a detailed study by Strobel and co-workers, it was demonstrated that 
substitution of the 2‟-position of c-di-GMP was detrimental for binding to class I 
riboswitch, Vc2 RNA.
23
 We have also revealed that the modification of the phosphate 
moiety of c-di-GMP decreased affinity for class I riboswitch Vc2 RNA,
26
 whereas 
binding to RocR (a phosphodiesterase) was not affected.
22
 Therefore it might be 
possible to design c-di-GMP analogs that could selectively bind to one class of c-di-







Figure 3.5 Co-crystal structure of c-di-GMP bound to Vc2 RNA (PDB code: 3IRW). 
C-di-GMP is shown in sticks and colored by atom (oxygen in red, nitrogen in blue, 
carbon in green and phosphorus in orange). Vc2 RNA is shown as surface and 
colored by atom (oxygen in red, nitrogen in blue and carbon in yellow). 
 
We investigated if the simultaneous modification of the phosphate and 2‟-position of 
c-di-GMP would additively abrogate binding to the class I riboswitch. Several 
binding assays to investigate the binding of c-di-GMP and analogs to RNA receptors 





 and fluorescent c-di-GMP sensor, based on Vc2 RNA 
riboswitch (class I)
38
. To gain a qualitative picture of the relative binding order of 
analogs, we opted to use the safer but qualitative fluorescent binding assay for c-di-
GMP or analog. The fluorescent c-di-GMP sensor would bind to c-di-GMP or analog 
in the riboswitch binding site and the binding event is transduced to another domain, 
which rearranges to bind to DFHBI, a molecule that is weakly fluorescent in water 




Figure 3.6). Using this class I riboswitch sensor, it was determined that the relative 
binding of c-di-GMP and analogs to class I riboswitch is as follows: c-di-GMP (3.1) 
> endo-S-c-di-GMP (3.2) > 2‟-F-endo-S-c-di-GMP (3.5) > 2‟-H- and 2‟-OMe-endo-
S-c-di-GMP (3.3 and 3.4), see Figure 3.7.  
 
Figure 3.6 C-di-GMP fluorescent riboswitch. Sequence of RNA is, 5‟-GAC GCG 
ACU GAA UGA AAU GGU GAA GGA CGG GUC CAG GC C GCA CAG GGC 
AAA CCA UUC GAA AGA GUG GGA CGC AAA GCC UCC GGC CUA AAC 
UUC GGU AGG UAG CGG GGU UAC CGA GC CUU GUU GAG UAG AGU 






Figure 3.7 Fluorescent c-di-GMP sensor screening for c-di-GMP and analogs (3.2 to 
3.5). Conditions: [RNA, SP_2] = 1 µM, [c-di-GMP and/or analogs] = 10 µM. Buffer: 
100 mM HEPES (pH 6.8) containing 100 mM NaCl, 100 mM KCl and 6 mM MgCl2. 







We conclude that the modifications of the phosphate and 2‟-position of c-di-GMP are 
additively detrimental to class I riboswitch binding. Curiously we note that this trend 
is also observed in the propensity to form G-quadruplexes (see Figures 3.2, 3.3 and 
3.4) and also the computed open:closed conformer ratio (Table 3.1). The computed 
energy differences between the various closed:open forms of c-di-GMP analogs (≤ 
2.2 kcal/mol) is however too small, compared to the binding affinity of c-di-GMP and 
the riboswitch (> 30 kcal/mol) so it is unlikely that the conformer distribution solely 
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Chapter 4.  Unexpected Complex Formation between 
Coralyne and Cyclic Diadenosine Monophosphate Providing a 
Simple Fluorescent Turn-on Assay to Detect This Bacterial 
Second Messenger 
(This chapter was published in Zhou et al. Anal. Chem. 2014, 86, 2412) 
 4.1 A simple and selective detection of c-di-AMP by coralyne 
4.1.1 Introduction 
Cyclic dinucleotides have come to the forefront of microbial research due to the 
impressive arrays of processes in bacteria that they regulate.
1-3
 For example, c-di-
GMP (the first cyclic dinucleotide to be discovered by Benziman almost three 
decades ago) has been shown to regulate motility, sessility and biofilm formation, 
virulence, cell cycle progression, heavy metal resistance, phage resistance, antibiotic 
resistance, quorum sensing amongst others in myriads of bacteria, including bacteria 
of clinical and military relevance.
4-6
 Due to the varied processes in bacteria that c-di-
GMP regulates, there has been an explosion of investigations aimed at unraveling 
processes, which are regulated by this nucleotide.
7
 Recently, another cyclic 
dinucleotide, c-di-AMP,
8,9
 has also stoked the interests of microbiologists as it has 
emerged that c-di-AMP is as important a second messenger in bacteria as c-di-GMP. 
C-di-AMP, originally discovered as a signaling molecule that controls DNA integrity 
in B subtilis has now been shown to regulate bacterial cell size and/or cell wall 
formation
8,10 






 In S. aureus, Listeria monocytogenes (L. 
monocytogenes) or B. subtilis, it has been shown that increased intracellular c-di-
AMP endowed these pathogens with the ability to resist β-lactam antibiotics whereas 
decreased intracellular c-di-AMP concentrations made the bacteria susceptible to 
antibiotics that target bacterial cell wall synthesis.
12-16
 In some bacteria, c-di-AMP 
also modulates ion transport across bacterial membranes and is hypothesized to 
modulate bacterial physiology as the concentration of metals in the environment 
changes.
17
 Apart from the aforementioned processes, c-di-AMP is also involved in 
resistance to acid
18
 and heat stress
19
 in some bacteria. In addition to controlling 
bacterial physiology, c-di-AMP also affects eukaryotic host cells and elicits type I 
interferon response.
20-22
 Unlike c-di-GMP, for which many of the protein and RNA 
receptors have been biochemically and biophysically characterized, the metabolism 
proteins and “adaptor/effector” proteins for c-di-AMP remain largely uncharacterized 
and the coming years will undoubtedly witness an explosion of biochemical and 
structural characterizations of c-di-AMP-related proteins and RNA. In this regard, 
tools that would aid the characterization of c-di-AMP receptors would help delineate 
the details of c-di-AMP signaling in bacteria. Herein, we provide a surprisingly 
simple fluorescent detection of c-di-AMP, using readily available coralyne (Figure 
4.1). We then demonstrate that this new assay can be used to monitor the synthesis c-
di-AMP by diadenyl cyclase (DAC), DisA
8
 as well as the degradation of c-di-AMP 
by the phosphodiestearses YybT
18
 and SVPD (snake venom phosphodiesterase). In 
addition to providing a practical detection of c-di-AMP, this work also suggests that 




different from the well-characterized complex formation between coralyne and linear 
polyadenine oligonucleotides.
23
  The interactions between aromatic heterocycles and 
DNA/RNA have been intensively studied for several decades due to the link between 
cancer and these planar intercalators.
24
 Many of these heterocyclic molecules are 
known to intercalate into Watson-Crick duplexes, whereas a few have also been 
reported to intercalate into non-Watson-Crick duplexes
25-27 
and higher order 




. In the past few years, efforts 
to design small molecules that could stabilize adenine-rich oligonucleotides have 
intensified due to potential biotechnological and medical applications of these 
molecules.
40-48
 For example, it has been demonstrated that adenine-rich 
oligonucleotides can form hydrogels in the presence of metals and that these 
hydrogels are responsive to pH changes.
49
 Polyadenylation is also known to play a 
role the progression of cancer and it has been known for more than a decade that 
tumor cells overexpress poly rA polymerases,
43
 suggesting that perhaps targeting poly 
rA could be a viable anti-cancer strategy.
50-53 
Poly A duplex formation in the presence 
of π-system is well known, however, formation of higher order structure with poly A 







Figure 4.1 Structures of c-di-AMP, c-di-GMP, pApA and coralyne. 
 
4.1.2 The quenching study of coralyne by halide ion  
Isoquinoline alkaloids, such as coralyne, are known to bind to adenine-rich 
oligonucleotides and stabilize adenine-adenine duplexes.
25,29,30,56-59 
In an important 
paper by Hud and co-workers, it was demonstrated that oligonucleotides containing 
long tracts of adenine, such as (dA)16 but not (dA)4, could bind to coralyne and form 
fibres.
56
 Subsequent works by others have revealed that the fluorescence of coralyne 




. In line with Hud‟s observation that 
short polyadenines do not bind coralyne,
56
 when coralyne was incubated with pApA 
(the degradation product of c-di-AMP by phosphodiesterases) or cAMP in a buffer 




profiles of coralyne (see Figure 4.2). On the other hand, when c-di-AMP (which 
contains the same number of adenine as pApA) was incubated with coralyne in the 
presence of KCl, both the UV and fluorescence intensities of coralyne increased (see 
Figure 4.2). It is known that when coralyne binds to polyadenine, its fluorescence 
and UV absorbance is decreased
41
 but here c-di-AMP enhanced the fluorescence and 
absorbance of coralyne, and this suggests that the binding mode between c-di-AMP 

















Figure 4.2 Fluorescence (a) and UV (b) profiles of coralyne in the presence of 
various nucleotides. Condition: [coralyne] = 10 µM, [nucleotides] = 40 µM, Buffer: 
50 mM Tris-H3PO4 (pH 7.5) containing 250 mM KCl. Temperature = 10 
o
C.  ex. 420 
nm, em. 475 nm. 
 
Although the fluorescence of coralyne was enhanced by c-di-AMP (~ 3 fold 






















































coralyne impeded our initial efforts to use coralyne to detect c-di-AMP 
concentrations lower than 20 µM (see Figure 4.3). We therefore sought ways to 
reduce the fluorescence of the unbound coralyne. We hypothesized that the 
fluorescence enhancement of coralyne, in the presence of c-di-AMP, was the result of 
coralyne intercalating between the two adenine bases of c-di-AMP. If this was the 
case, then it was expected that the bound coralyne would be protected from 
fluorescence quenchers whereas the unbound coralyne could be readily quenched by 
anions. Therefore it would be possible to increase the signal-to-noise ratio of c-di-
AMP detection using anion-quenching phenomenon.  
 
Figure 4.3 The fold fluorescence of coralyne in the presence of c-di-AMP. In the 
absence of a halogen quencher the unbound coralyne is also fluorescent and therefore 
changes in fluorescence intensity in the presence of different concentrations of c-di-
AMP are not large. For example, the fluorescence fold changes for 10 µM c-di-AMP 
and 20 µM c-di-AMP or 20 µM and 40 µM are almost similar. The addition of 
bromide or iodide improves the discrimination between different c-di-AMP 
concentrations (see Figure 4.10).  Condition: [coralyne] = 10 µM, Buffer Tris-H3PO4 
(pH 7.5), [c-di-AMP] = 0, 5, 10, 20 or 40 µM. Temperature = 10 
o






The quenching of coralyne by KBr in absence of c-d-AMP is dominantly static with 
Ks of 101.2 M
-1
 (from intercept of modified SV plot, 110.2 M
-1
 – 9.03 M
-1
 ≈ 101.2 M
-
1
 ) compared with dynamic constant of 9.03 M
-1
 (lifetime data, 0.00903 mM
-1
 = 9.03 
M
-1
), see Table 4.1 and Figure 4.4. After complexing with c-d-AMP the quenching is 





 = 0.918 M
-1





 = 0.512 M
-1
), see Table 4.1 and Figure 4.5. For 
construction of the Stern-Volmer plot, we used average lifetime from two-component 
fit. There is a slightly better fit with three-exponential, which reveals a long lifetime 















Figure 4.4  (a) KBr quenching of coralyne in 50 mM Tris-H3PO4 Buffer (pH 7.5) at 
25 
o
C. The squares show the values of relative intensity and circles of lifetimes.  (b) 
Modified Stern-Volmer plot for quenching of Coralyne with KBr.  
 










































































Figure 4.5 KBr quenching of coralyne in presence of 40 μM of c-d-AMP at 25 
o
C. 
Buffer: 50 mM Tris-H3PO4 (pH 7.5). Squares are intensity and circles are lifetime 
data. 
 
The quenching of coralyne by KI in absence of c-d-AMP is also dominantly static 
with Ks of 35,860 M
-1
 (intensity data, 35.86 mM
-1
 = 35,860 M
-1
) compared with 
dynamic constant of 912.0 M
-1
 (lifetime data, 0.912 mM
-1
 = 912.0 M
-1
), see Figure 
4.6. After complexing with c-d-AMP the quenching by KI is significantly reduced 
(see Figure 4.6); from intensity measurements that include static and dynamic 




 = 25.6 M
-1





 = 6.4 M
-1
). Overall, KI is significantly stronger quencher than 
KBr for coralyne and similar quenching effect can be obtained with ~ 100 times 
lower concentration compared to KBr.  However, KI also partially quenches coralyne 
even when c-di-AMP is present so for our c-di-AMP detection, we decided to use 
KBr as the quencher. 
 
y = 0.000918x + 0.9959
R² = 0.7779

















































Table 4.1 Fluorescence quenching of coralyne with KBr. ex. 445 nm, em 480/30 nm. 
 
























0  14.22 1 14.2 1.92 
1 n/a n/a n/a n/a n/a n/a I=242 9.82 0.317 
  
I=228 <32> 0.683 24.97 1.16 
10 11.56 1 11.56 1.45 1.23 12.13 1 12.13 30 
 
428 
I=96 9.66 0.562 
  
(2.38) 2.33 0.137 
   
 
<32> 0.438 19.45 1.07 
 
19 0.863 16.73 1.86 1 
      
1.29 0.072 
   
      
5.92 0.131 
   
      
28.73 0.797 23.76 1.04 
 
25 9.86 1 9.86 1.3 1.44 12.39 1 12.04 31 
 
411 
I=48 8.96 0.744 
  
(4.75) 2.5 0.136 
   
 
<32> 0.256 14.86 1.04 
 
19.43 0.864 17.11 1.4 0.98 




      
6.79 0.144 
   
      
30.52 0.781 24.52 1.21 
 
50 8.62 1 8.62 1.24 1.65 12.04 1 12.04 25 
 
420 
I=14.3 7.57 0.697 
  
(15.94) 2.31 0.139 
   
 
<32> 0.303 14.97 1.11 
 
18.58 0.861 16.32 1.54 1.02 




      
7.04 0.148 
   
      
31.3 0.779 25.52 1.21 
 
75 7.11 1 7.11 1.37 2 11.9 1 11.9 26 
 386 
I=12.3 4.11 0.228 
  
(18.54) 2.49 0.141 





8.22 0.772 7.29 1.12 
 
18.63 0.859 16.35 1.6 1.02 




      
6.82 0.154 
   
      
33.67 0.782 27.46 1.14 
 
100 6.67 1 6.67 1.35 2.13 11.89 1 11.89 27 
 
387 
I=6.6 2.18 0.131 
  
(34.55) 2.5 0.142 
   
 
7.19 0.869 6.53 1.03 
 
18.7 0.858 16.4 1.51 1.02 




      
6.33 0.149 
   
      
30.39 0.784 24.86 1.06 
 
250 4.38 1 4.38 3.77 3.25 11.36 1 1 28 
 
317 
I=3.9 6.19 0.506 
  
(58.46) 2.37 0.152 
   
 
2.02 0.494 4.13 1.03 
 
16.96 0.848 14.75 1.69 1.13 




      
5.14 0.153 
   
      
23.05 0.759 18.37 1.09 
 
Condition: [coralyne] = 10 µM, [c-di-AMP] = 40 µM, Buffer: 50 mM Tris-H3PO4 
(pH 7.5) at 25 
o








Figure 4.6 KI quenching of Coralyne fluorescence in absence (a) and presence of 40 
μM c-d-AMP (b) at 25 
o
C. Buffer: 50 mM Tris-H3PO4 (pH 7.5) 
 
4.1.3 The complex formation between coralyne and c-di-AMP 
At higher temperature (60 
o
C), c-di-AMP did not “protect” coralyne from fuorescence 
quenching by bromide or iodide and the value of I0/I was ~1 (see Figures 4.7 and 
4.8). This observation suggests that coralyne forms a supramolecular inclusion 
complex with c-di-AMP but at higher temperatures, the complex is not stable and 
y = 35.86x + 0.1405
R² = 0.9947










































y = 0.0256x + 1.1026
R² = 0.9876











































hence coralyne would no longer be protected from halide quenching at high 
temperatures.  
 
Figure 4.7 KI quenching in the absence of c-di-AMP or in the presence of c-di-AMP 
at 60 
o
C. Condition: [coralyne] = 10 µM, [c-di-AMP] = 0 or 40 µM, Buffer: 50 mM 
Tris-H3PO4 (pH 7.5) containing KI = 1 or 100 mM. ex. 420 nm, em. 475 nm. 
 
In contrast to the data at 10 
o
C (Figure 4.8), where c-di-AMP “protected” coralyne 
from quenching, at 60 
o
C, KI can quench the fluorescence of coralyne even in the 
presence of c-di-AMP. This is consistent with a model whereby coralyne forms a 
complex with c-di-AMP to become “protected” from quenching but at higher 
temperature, the complex would collapse and hence the protection from quenching 
































































Figure 4.8 KI quenching in the absence of c-di-AMP or in the presence of c-di-AMP 
at 10 
o
C. Condition: [coralyne] = 10 µM, [c-di-AMP] = 0 or 40 µM, Buffer: 50 mM 
Tris-H3PO4 (pH 7.5) containing KI = 1 or 100 mM. ex. 420 nm, em. 475 nm. 
 
C-di-AMP could be detected with coralyne at both acidic and basic pH (see Figure 
4.9), although the fold fluorescence increase at basic pH 9.2 (22.4), was slightly better 
than at pH 7.5 or 4.5 (13 and 14.5 respectively). Having established that the inclusion 
of a bromide quencher and conducting the c-di-AMP detection assay at pH 9.2 was 
optimal for sensitive detection, we proceeded to investigate if c-di-AMP 
concentrations lower than 40 µM could be detected with our new system. Pleasing 
lower concentrations of c-di-AMP (down to 5 µM) could be detected using our 
system, see Figure 4.10. This simple fluorescent detection system could therefore be 
suitable for determining the enzymatic proficiencies of c-di-AMP synthases or 





















































Figure 4.9 Fold fluorescence profiles of coralyne in the presence of c-di-AMP at 
different pHs. Condition: [coralyne] = 10 µM, [c-di-AMP] = 40 µM, Buffer: 50 mM 
Tris-H3PO4 (pH 4.5, 7.5 or 9.2), containing 250 mM KBr. Temperature = 10 
o
C. ex. 
420 nm, em. 475 nm.  
 
 
Figure 4.10 The fluorescence of coralyne is proportional to the concentration of c-di-























































µM, Buffer: 50 mM Tris-H3PO4 (pH 9.2) containing 250 mM KBr, showing c-di-
AMP concentration dependence on fluorescence enhancement. Temperature = 10 
o
C. 
ex. 420 nm, em. 475 nm. Measurements were done in triplicate. 
 
Circular dichroism (CD) is an excellent tool to study structural perturbations that 
result from the association of a chiral molecule with another molecule. The CD 
spectrum of c-di-AMP in the absence of coralyne is different from in the presence of 
coralyne (Figure 4.11). Upon the addition of coralyne to c-di-AMP, both the negative 
and positive CD bands of c-di-AMP increase, indicating that both the helicity and π-π 
stacking interactions in c-di-AMP changes upon the addition of coralyne. An increase 
in the CD band is indicative of increased π-π stacking (presumably due to coralyne-
adenine π-π stacking). For pApA, however, there is no difference between the 
presence and absence of coralyne (see Figures 4.11 and 4.12). This CD data 
augments the UV and fluorescence data, which suggested that coralyne associates 
with c-di-AMP but not with pApA (refer to Figure 4.2). Whereas the inability of 
pApA to form a complex with coralyne, at the tested micromolar concentrations, was 
in line with earlier studies by Hud et al.
56
 the complex formation between the cyclic 
dinucleotide, c-di-AMP, and coralyne was unexpected. To gain some insights into the 
stiochiometry of the c-di-AMP/coralyne complex, we performed a Job plot analysis 
(Figures 4.13 and 4.14). This analysis revealed that c-di-AMP forms a higher order 
complex with coralyne (not the expected 2:1 complex that would have been predicted 






Figure 4.11 CD of coralyne-c-di-AMP or pApA complex. Condition: [coralyne] = 10 
µM, [c-di-AMP] = 40 µM, Buffer: 50 mM Tris-H3PO4 (pH 7.5) containing 250 mM 
KBr. Coralyne plus c-di-AMP or pApA indicates coralyne incubated with c-di-AMP 
or pApA with incubation conditions listed in experimental section. 
 
Figure 4.12 CD of coralyne-c-di-AMP or pApA complex (220-700 nm). Condition: 
[coralyne] = 10 µM, [c-di-AMP] = 40 µM, Buffer: 50 mM Tris-H3PO4 (pH 7.5) 



































Figure 4.13 Job plot of coralyne and c-di-AMP interaction. [coralyne] + [c-di-AMP] 
was fixed at 50 µM. The experiment was done in triplicate and plotted together on the 
graphs. Buffer: 50 mM Tris-H3PO4 (pH 7.5) containing 250 mM KBr. Temperature = 
10 
o







































Figure 4.14 Job plot. [coralyne] + [c-di-AMP] was fixed at 50 µM. The experiment 
was done in triplicate and plotted together on the graphs. Buffer: 50 mM Tris-H3PO4 
(pH 4.5, Figure 4.14a or pH 9.2, Figure 4.14b) containing 250 mM KBr. 
Temperature = 10 
o
C. ex. 420 nm, em. 475 nm.  
 
To corroborate the Job plot data, which indicated that c-di-AMP forms higher order 
supramolecular aggregate in the presence of coralyne, we proceeded to conduct NMR 
titration experiment. The addition of only 0.1 equivalence of coralyne to c-di-AMP, 
in the presence of potassium cations (100 mM) resulted in the complete 
disappearance of the c-di-AMP 
1
H NMR peaks around 8.24, 7.98 and 6.01 ppm (see 
Figure 4.15). The complete disappearance of the proton NMR peaks is indicative of 
polymer formation. The complete disappearance of the c-di-AMP peaks in the proton 
NMR (Figure 4.15) when only 0.1 equivalence of coralyne was added cannot be 
explained by a 2:1 complex between c-di-AMP and coralyne; a 2:1 complex between 
c-di-AMP and coralyne would have expected molecular weight of 1676.34, which 





stiochiometry that is or greater than 6:1. Adenine is known to form hydrogen bonds 









. Adenine tetrads, which usually contain 
four hydrogen bonds per tetrad, are not as stable as G-tetrads (which contain eight 
hydrogen bonds per tetrad). Could coralyne promote A-tetrad formation by c-di-
AMP? It has been shown that the formation adenine tetrads could be facilitated if the 
A-tetrad could π-stack with a proximal G-quadruplex.
67
 Analogously, it is plausible 






H NMR spectra of c-di-AMP with (a) or without (b) coralyne. Addition 
of coralyne (0.1 equiv.) to c-di-AMP caused complete disappearance of the c-di-AMP 
peaks in the 
1
H NMR spectrum (spectrum a). Condition: [coralyne] =0 or 40 µM, [c-




4.1.4 The biological application of coralyne assay 
Because c-di-AMP plays an important role in bacterial cell wall formation and 
susceptibility to antibiotics, which target cell wall formation, it is of interest to 




ultimate goal that the inhibition of the synthases or phosphodiesterases could 
potentiate the activities of antibiotics, such as the β-lactams. We therefore 
investigated if coralyne could be used to assay the activities of c-di-AMP metabolism 
enzymes. It has been demonstrated that the PDE enzyme, YybT, is a c-di-AMP 
phosphodiesterase
18
 whereas DisA is a c-di-AMP synthase.
8
 We incubated YybT with 
c-di-AMP (40 µM) and stopped the reaction at 1 min and 30 min. We then used our 
newly developed c-di-AMP detection assay to investigate the c-di-AMP cleavage 
reaction, Figure 4.16b. As a control, c-di-AMP (40 µM) was also treated with snake 
venom phosphodiesterase and the cleavage reaction analyzed with our coralyne assay. 
Pleasingly, our assay revealed that under the reaction conditions, YybT (10 µM) 
cleaved the majority of the c-di-AMP (40 μM) within 1 min, see Figure 4.16b. 
Coralyne can also be used to monitor the synthesis of c-di-AMP from ATP by 





Figure 4.16 (a) Conversion of ATP into c-di-AMP by DisA. DisA (10 μM) was 
added to  ATP (100 μM) in 200 mM Tris-HCl, pH 7.5, 100 mM NaCl and 10 mM 
MgCl2 at 30 °C. Reactions were stopped at 1 min, 2 min, 5 min, 7 min, 10 min, 15 
min, 20 min and 30 min and incubated with conditions stated in the experimental part. 
The fluorescence was subsequently measured; (b) Cleavage of c-di-AMP by YybT 
and SVPD. YybT (10 μM) in 100 mM Tris-HCl, pH 8.3, 20 mM KCl, 500 μM 
MnCl2, 1 mM DTT or SVPD (1 mg/mL) in 50 mM Tris-HCl, pH 8.8 and 15 mM 
MgCl2 were used to cleave c-di-AMP (100 μM) at 37 °C. Reactions were stopped at 1 
min and 30 min and incubated with conditions stated in the experimental part. 



















































In our continuing efforts to investigate the interactions of heterocycles with bacterial 
dinucleotide second messengers we uncovered an unexpected interaction of coralyne 
with c-di-AMP but not the linear analog pApA, which also contains two rA. Although 
we have been unable to define the exact nature of the complex between coralyne and 
c-di-AMP, due to possible polymer formation, the optical properties of this 
supramolecular complex has facilitated the detection of c-di-AMP, which could be 
useful for c-di-AMP research. Nucleotide signaling has emerged as important in 
bacteria and regulates diverse bacterial phenotypes. Currently there are efforts to 
identify and characterize both synthase and phosphodiesterases of c-di-AMP and it is 
believed that c-di-AMP metabolism enzymes could become new drugable targets that 
could potentiate the effects of cell wall modifying antibiotics. Herein, we demonstrate 
an alternative non-radioactive assay to study the enzymatic proficiencies of c-di-AMP 
metabolism proteins (DAC and PDE). This simple fluorescent assay could also be 
adapted for a high-throughput screen for c-di-AMP phosphodiesterase inhibitors, 
which are expected to potentiate the killing effects of peptidoglycan inhibition drugs. 
This work also demonstrates that although at low micromolar concentrations, small 
nucleotides are not known to readily associate with heterocyclic intercalators (unlike 
polynucleotides), circularization of dinucleotides appear to enhance aggregate 
formation. Plausibly, the high entropic cost associated with bringing many small 
nucleotides together for complex formation, is reduced upon circularization because 




under-utilized strategy, which might improve oligonucleotide association kinetics or 





4.2 Synthesis of c-di-AMP  
We chose to prepare c-di-AMP using a modified version of solution phase synthesis 
(Scheme 4.1) similarly to the synthesis of c-di-GMP.
68
 Two portion of adenosine 
phosphoramidites (2 g) were used for the steps and reaction mixture was concentrated 
and then re-dissolved in water (5 mL), purified by HPLC (Merck Purosphser® STAR 
RP-18 column) with HPLC condition: 5-20% B, 0-16 min (A: 0.1 M TEAA in water; 
B: acetonitrile, pH 7.0), concentrated at a reduced pressure, and washed with acetone 
(2 mL × 5) to remove the excess of TEAA buffer.  
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Chapter 5. Conclusion and Future Directions 
With such overwhelming pieces of evidence to support the fact that increased 
intracellular concentrations of c-di-GMP lead to biofilm formation, one can safely 
assume that the disruption of c-di-GMP signaling would provide an effective means 
to disrupt biofilm and/or virulence factor formation in several bacteria of clinical 
relevance. C-di-GMP however achieves the regulation of bacterial phenotype via 
binding to several effector molecules including transcription factors, enzymes and 
riboswitches. Some of these c-di-GMP receptors have opposing effects. For example, 
whereas inhibiting a DGC would likely lead to biofilm reduction, inhibiting a PDE 
would increase biofilm formation. Thus the selective inhibition of c-di-GMP receptor 
proteins becomes critical for effective biofilm control. Crystal structure analyses of c-
di-GMP effector molecules, in complex with the ligand, reveal that various classes of 
c-di-GMP receptors recognize this dinucleotide using different sets of recognition 
elements. Therefore, it is plausible that different analogs of c-di-GMP could be used 
to selectively modulate a specific class of c-di-GMP binding receptors, and hence 
modulate the bacterial phenotype. In Chapter 2, I reported that we prepared various 
2‟-modified analogs of c-di-GMP and studied both polymorphisms of these analogs 
using DOSY NMR and the binding to several effector proteins, such as PilZ-
containing proteins, DGC containing I-sites, and PDE. 2‟-modification of c-di-GMP 
did not adversely affect the propensity to form higher aggregates, such as octameric 
forms, in the presence of potassium salts. Interestingly, we found that the selective 
binding to different classes of c-di-GMP binding proteins could be achieved with the 




DGCs better (four times) than the native dinucleotide, c-di-GMP, whereas c-di-GMP 
binds to PDEs better (10 times) than 2‟-F-c-di-GMP. Since unmodified c-di-GMP can 
hardly penetrate the intact plasma membrane, it is imperative that any future efforts 
aimed at using c-di-GMP analogs for in vivo perturbation of nucleotide signaling uses 
cell permeable analogs of c-di-GMP.  
 
Several strategies to make cell-permeable analogs of c-di-GMP could be envisioned 
and one, currently being pursued by a new member of the Sintim group, is to install a 
caging group, 6-nitropiperonyl diazo
1
 on c-di-GMP (Scheme 5.1).  The chemistry is 
based on the enhanced reactivity of diazomethyl group toward phosphates, compared 
to the other functional groups on the molecule.
2 
Caged c-di-GMP could be uncaged 
with light.
3
 Photocaged c-di-GMP would be valuable for studies related to how global 
increase in intracellular c-di-GMP would affect bacterial physiology. Many of the c-
di-GMP metabolism proteins, have additional domains that are involved in other 
protein-protein interactions so studies that use over-expression of these proteins to 
study the effects of increased c-di-GMP concentrations are plagued with secondary 
effects that are different to disentangle. Photocaged c-di-GMP analogs are however 
not viable drug candidates, especially ones that need near-UV light or even visible 
light for uncaging because of toxicity or tissue penetration problems respectively. An 
alternative strategy to make cell permeable analogs of c-di-GMP or related 
dinucleotides might include moieties on the phosphate group, which could be 
deprotected in vivo via enzymatic means. This strategy has been used extensively for 












Beyond dinucleotide analogs, other small molecules could also be developed as 
inhibitors of dinucleotide signaling. The identification of a new lead compound for 
optimization is non-trivial and typically involves massive screening exercises, using 
large compound libraries with diverse collections. To facilitate the identification of c-
di-GMP signaling inhibitors, previous members of the Sintim group developed 
innovative fluorescence-based assays that lend themselves to high-throughput 
screening, such as the thiazole orange assay for detecting c-di-GMP. During my PhD 
training, I also developed a surprisingly simple fluorescent assay for detecting c-di-




stage is now set to discover new inhibitors of bacterial nucleotide signaling pathways. 
New members of the Sintim group are now utilizing the TO and coralyne assays to 
discover non-nucleotide-based inhibitors of various c-di-GMP metabolism proteins. 
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Chapter 6. Experimental Section 
6.1 General procedure 
6.1.1 General reaction conditions 
Reactions were carried out in oven-dried glassware, stirred with teflon-coated 
magnetic stir bars and sealed with rubber septa under a positive pressure of anhydrous 
argon. High temperatures were obtained using silicone oil baths and monitored by a 
thermometer or under dry heating block with temperature controlled electronically. 
Organic solutions were all concentrated using a Büchi rotary evaporator. High boiling 
solvents (H2O or DMF) were removed under high vacuum for 0.5–1.5 hours. 
6.1.2 Preparation of dry solvents 
Dry acetonitrile and pyridine were obtained from distillation over CaH2 and dried 
overnight with drying kit containing molecular sieves (4Å) purchased from 
Chemegenes prior to use. Dry DMF was directly purchased from Sigma-Aldrich 
without further purification.   
6.1.3 Reagents 
Phosphoramidites and Beaucage Reagent were purchased from Chemgenes and/or 
Glen Research. 2‟-OMe-c-di-GMP was purchased from Axxora. Columns used in 
HPLC as well as C18-coated silica-gel packing material were obtained from 
Nacalai
®
. Solvent used in HPLC were purchased from VWR and/or Fisher Scientific. 
Other reagents including intercalator coralyne were all purchased from Sigma-





HPLC was performed with a Varian 210 system equipped with a UV detector. 
Samples were all filtered by a 0.2 μm syringe filter (PTFE) prior to the injection. 
 
NMR spectra were measured on Bruker AV-400, Bruker DRX-400, Bruker DRX-500 
or Bruker AVIII-600. Data for 1H-NMR spectra are reported as follows: chemical 
shift (ppm, relative to residual solvent peaks or indicated external standards; s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constant (Hz), 
and integration. Coupling constants were rounded to 0.5 Hz. 2D COSY experiments 
were carried out with Bruker AVANCE II at 600 MHz, 30 °C. Pulse sequence used in 
“COSYGPMFPH‟ from Bruker TOPSPIN 2.1, double quantum filtered COSY.  The 
size of matrix is 4096 by 320, with 52 scans on each serial file. The FID resolutions 
are 1.1 Hz and 13.9 Hz for F2 and F1 domains, respectively. Linear Prediction was 
used for F1 domain to 2K points. 2D DOSY experiments were carried out with 
Bruker AVANCE II at 600 MHz, 30 °C.  The concentration of the samples was 3 mM 
in D2O (with or without K
+
). After the addition of KCl, the samples were heated and 
then kept at 95°C for 5 min, cooled down to room temperature, and stored at 4 °C for 
overnight before use. Shigemi NMR tubes (D2O) were used for all experiments. 
DOSY was measured with the stimulated echo pulse sequence (Bruker pulse program 
stebpgp1s19) using bipolar gradient pulses and watergate 3-9-19 to suppress the 
solvent. Key aquisition parameters for the DOSY experiment include the big delta (Δ) 
at 0.09 s, the number of scans at 32, relaxation delay at 2.5 s, and the gradient 




delta δ) within the range of 1.4–1.8 ms was optimized under the experiment condition 
until the region of 6.0–9.0 ppm showed good decays for the major peaks. The data 
were processed with TopSpin 2.1 software with T1/T2 relaxation analysis. 
Exponential function was applied for the raw data and the curve-fitting of the decays 
was based on the area of the peaks. Shigemi NMR tubes (D2O) were used for all 
experiments, in which 0.30 mL sample solution was applied. 
 
Mass spectra (MS) were recorded by JEOL AccuTOF-CS (ESI positive and negative 
modes). High resolution mass spectra (HRMS) for ESI spectrometer were calibrated 
with an aqueous solution of PEG600.  
 
UV absorbance spectra were obtained on a JASCO V-630 spectrophotometer with 1 
cm path length cuvette. The concentration of a stock solution of c-di-GMP and 





 as a molar extinction coefficient. The concentrations of c-di-AMP and analogs 





a molar extinction coefficient.  
 
Fluorescence measurements were carried out on a Cary Eclipse fluorescence 






Circular dichroism (CD) experiments were performed on a JASCO J-81 
spectropolarimeter with 1 cm path length cuvette. 
 
Fluorescence lifetime was measured using a time-domain system integrated with a 
fluorescence lifetime imaging microscope (FLIM) system Alba V (ISS, Urbana, IL). 
The system is equipped with a SPC-830 TCSPC module and pulsed laser system 
(Becker and Hickl GmbH). Laser BHL-445 nm and observation through band-pass 
filter 485/30 nm was used. Data analysis was performed using Vista Vision software 
v. 218 from ISS. 
 
DNA/RNA synthesizer (ABI Applied Biosynthesis 392) was used for making 


















6.2 Synthetic protocols for compounds in Chapter 2-4 
6.2.1 Synthesis of 2’-modified c-di-GMP analogs in Chapter 2 
Synthesis of 2‟-modified c-di-GMP is summarized in Scheme 2.1. Literature 
procedure
2
 was used but with a slight modification. Two portion of guanosine 
phosphoramidites (2 g) were used for the steps up until intermediate 2.11 or 2.12 
before the first purification was done. After mono-cyanoethyl protected 2.11 or 2.12 
was obtained, the solvent was removed from the reaction mixture by high vacuum to 
yield a sticky yellow solid. This crude material was transferred to a centrifuge tube 
and was sequentially washed with EtOAc (50 mL × 2), MeOH (50 mL × 3) and 
centrifuged each time. The EtOAc layer was extracted with H2O (25 mL × 2), and the 
aqueous layer combined with the MeOH layer and was concentrated and subjected to 
HPLC purification (Nacalai tesque® 5C18-PAQ column). HPLC condition: 20-35% 
B, 0-20 min (A: 0.1 M TEAA in water; B: acetonitrile, pH 7.0). The product was 
identified by ESI-MS (negative mode), collected and immersed in ammonia (28 % 
NH4OH in water, 15 mL) at 40 °C for overnight. The crude product was concentrated 
and then re-dissolved in water (5 mL), purified by HPLC (Nacalai tesque 5C18-PAQ 
column), HPLC condition: 113% B, 0 17 min (A: 0.1 M TEAA in water; B: 
acetonitrile, pH 7.0), concentrated at a reduced pressure, and washed with acetone (2 
mL × 5) to remove the excess of TEAA buffer. To extensively remove TEAA, the 
product was collected and washed with cation exchange resin, DOWEX®, Na+ form. 
100 mg product of 2.2 and 2.3 were collected with estimated yield of 10%. 2‟-F-c-di-
GMP and 2‟-H-c-di-GMP were firstly synthesized and characterized by Dr. Jingxin 
Wang as the TEA salt in his PhD dissertation.
3




GMP affects binding to biological receptors so I spent some time designing protocols 
to remove the TEA cation and replacing with sodium cation.  The 
1
H NMR spectrum 
for the c-di-GMP analogs with Na cation compounds were similar to that obtained by 
Dr. Wang,
3
 the only difference being that there were no peaks related to TEA. COSY 
and DOSY NMR were further used to determine the coupling constant between H1‟ 
and H2‟ presented in Table 2.3 in Chapter 2.  
 
2’-F-c-di-GMP sodium salt (2.2) 
1
H NMR (600 MHz, D2O, water suppression) δ 
8.31 (s, 2H), 6.56 (d, J
3
 H–F = 19 Hz, 2H), 5.85 (d, J
1
 H–F = 51, 2H), 5.32 – 5.28 (m, 





2’-H-c-di-GMP sodium salt (2.3) 
1
H NMR (400 MHz, D2O, water suppression, 60 
o
C) δ 8.36 (s, 2H), 6.62 (m, 2H), 5.39 (s, 2H), 4.58 (s, 2H), 4.46-4.40 (m, 4H), 3.28 
(s, 2H), 3.07-3.04 (m, 2H).  
6.2.2 Synthesis of endo-S-c-di-GMP analogs in Chapter 3 
Synthesis of endo-S-c-di-GMP analogs (3.3 to 3.5) is summarized in Scheme 3.1. 
They were synthesized and characterized by Dr. Jingxin Wang and I together. The 
characterizations of endo-S-c-di-GMP analogs (3.3 to 3.5) can be found in Dr. 
Jingxin Wang‟s PhD dissertation.
3
 The DOSY NMR and binding studies with RNA 
riboswitch were performed by me.  
6.2.3 Synthesis of c-di-AMP in Chapter 4 
C-di-AMP was synthesized by adopting literature procedures with slight 
modifications.
2
 Two portion of adenosine phosphoramidites (2 g) were used for the 
steps and reaction mixture was concentrated and then re-dissolved in water (5 mL), 
purified by HPLC (Merck Purosphser® STAR RP-18 column) with HPLC condition: 
5  20% B, 0 16 min (A: 0.1 M TEAA in water; B: acetonitrile, pH 7.0), 
concentrated at a reduced pressure, and washed with acetone (2 mL × 5) to remove 







H NMR (600 MHz, D2O, water suppression) δ 8.21 (s, 2H), 7.88 
(s, 2H), 5.97 (s, 2H), 4.41 – 4.36 (m, 2H), 4.04-4.02 (m, 4H).  
31
P NMR (202 MHz, 






















6.3 Computational data 
All of the calculations were performed with the Gaussian 03/09 program.
4
 
Calculations of the radii of 2‟-modified c-di-GMP analogs (2.2 and 2.3) in their 
different aggregation states were reported in Table 2.1 and 2.3 in Chapter 2. 
Computed energy differences between “open” and “closed” forms of c-di-GMP (3.1) 


























6.4 Biophysical data 
6.4.1 Sample preparation for spectrometric and optical measurements in 
Chapter 2 
C-di-GMP or c-di-GMP analogs, water and 50 mM tris-HCl buffer solution (pH 7.5)  
containing 250 mM KCl were mixed, heated and kept at 95 ºC for 5 min, cooled back 
to room temperature and then incubated in refrigerator for 12 h for spectrometric and 
optical measurements. 
6.4.2 Sample preparation for spectrometric and optical measurements in 
Chapter 3 
C-di-GMP or analogs and DFHBI concentrations were determined via UV 









 (DFHBI) were used as extinction coefficients to 
calculate concentrations. RNA in buffer solution was heated to 80 °C for 5 min and 
cooled down to room temperature in 15 min. Then MgCl2 and c-di-GMP were added 
and the sample was kept for 12 h at room temperature. DFHBI was added to samples 
and fluorescence was monitored by excitation at 496 nm and emission at 501 nm. 
6.4.3 Sample preparation for spectrometric and optical measurements in 
Chapter 4 
C-di-AMP or pApA, water, buffer solution (Tris-HCl or Tris-H3PO4), and metal 
solution (KCl, KBr or KI) were mixed, heated, kept at 95 °C for 5 min, and cooled 
back to room temperature, and coralyne was added. The samples were then incubated 








 as a molar extinction 
coefficient for both compounds. Fluorescence measurements and Circular dichroism 
(CD) experiments were carried out at 10 °C, with λex = 420 nm (slit 5 nm) and λem = 
430−700 nm (slit 5 nm). The concentration of c-di-AMP or pApA was 40 μM; 
coralyne was 10 μM, and buffer was 50 mM Tris-H3PO4 (pH 4.5, 7.5, or 9.2) 


















6.5 Biological data 
6.5.1 Enzymatic Assay in Chapter 2 
(Ms. Sarah Watt from the Lee group is acknowledged for contributing to the 
experimental section related to the assay to determine binding to DGC and PDE 
proteins). 
 
Determination of half maximal inhibitory concentration (IC50) 
IC50 for each compound was determined by adding 0.8 nM of the 
32
P-c-di-GMP to 2 
µL of unlabeled c-di-GMP analogs at varying concentrations. Compounds were tested 
at concentrations ranging from 200 µM to 0 µM made through 2-fold serial dilutions. 
The proteins Alg44 at 2.5 µM and WspR at 10 µM were added to each probe and 
competitor mixture in a buffer containing 10 mM Tris pH 8.0, 100 mM NaCl, and 5 
mM MgCl2. The protein RocR at 2.5 µM was added to each probe and competitor 
mixture in a buffer containing 10 mM Tris pH 8.0, 100 mM NaCl, and 5 mM CaCl2 
to prevent hydrolysis. These reactions were incubated for five minutes and then 
spotted on nitrocellulose paper.
5
 Once dry, these spots were exposed to a 
phosphorimager film for 10 minutes before being examined by a FLA7100 Fujifilm 
Life Science PhosphorImager and quantified using Fujifilm Multi Gauge software 
v3.0.  The IC50 was determined by the inhibitor vs. response equation in the Prism 5 
software.   
 




The activities of diguanylate cyclases WspR and PA1107 were monitored by thin 
layer chromatography as described.6 
32
P-GTP was added to a mixture of the inhibitor 
at the indicated concentration and 9 µM WspR in 10 mM Tris, pH 8.0, 100 mM NaCl 
and 5 mM MgCl2 and incubated for 120 minutes at 30˚C. One microliter of the 
mixture is spotted on cellulose thin layer plate and separated in a chamber with a 
buffer containing 1.5 volume of 1.5 M K2HPO4 and 1 volume of saturated 
(NH4)2SO4. The polyethylenimine-modified (PEI) cellulose TLC plate was dried, 
exposed to phosphorimager screen, examined using FLA7100 Fujifilm Life Science 
PhosphorImager and quantified using Fujifilm Multi Gauge software v3.0. 
 
Inhibition of phosphodiesterase activity 





P-c-di-GMP was added to a mixture of the inhibitor 
at the indicated concentration and 4.5 µM RocR in 10 mM Tris, pH 8.0, 100 mM 
NaCl and 5 mM MgCl2 and incubated for 120 minutes at 22 ˚C. One microliter of the 
mixture is spotted on cellulose thin layer plate and separated in a chamber with buffer 
containing 1.5 volume of 1.5 M K2HPO4 and 1 volume of saturated (NH4)2SO4. The 
PEI cellulose TLC plate was dried, exposed to phosphorimager screen, examined 
using FLA7100 Fujifilm Life Science PhosphorImager and quantified using Fujifilm 
Multi Gauge software v3.0. 
 




For the WspR diguanylate cylcase activity, mixtures of 
32
P-GTP and the unlabeled 
GTP were used as the substrate and c-di-GMP or 2‟-F-c-di-GMP was used as the 
inhibitor occupying the allosteric I-site. The activity of the WspR was monitored by 
thin layer chromatography as described above for one hour at 37˚C. The initial rate of 
reaction (V0) for each enzyme was determined by measuring the slope of the initial 
time points for each of the indicated substrate and inhibitor concentration. For each 
inhibitor concentration, the V0 was plotted against the substrate concentration. The 
Vmax and Km reported in Table 2.4 was calculated by non-linear regression analysis 
using Prism Graphpad software. 
 
6.5.2 Enzymatic Assay in Chapter 4 
DisA and YybT were expressed in BL21(DE3) and purified by Nickel-affinity 
chromatography column (GE Healthcare). DisA was dialyzed into a 10 mM Tris-HCl, 
pH 8.0, and 100 mM NaCl solution, and YybT was dialyzed into a 50 mM Tris-HCl, 
pH 8.0, and 150 mM NaCl solution. Phosphodiesterase I from Crotalus adamanteus 
venom (snake venom phosphodiesterase, SVPD) was purchased from Sigma-Aldrich. 
For the c-di-AMP synthesis assay, DisA (10 μM) was added to 100 μM ATP in 40 
mM Tris-HCl, pH 7.5, 100 mM NaCl, and 10 mM MgCl2 at 30 °C.7 For the c-di-
AMP cleavage assay, YybT (10 μM) in 100 mM Tris-HCl, pH 8.3, 20 mM KCl, 500 
μM MnCl2, and 1 mM DTT17 or SVPD (1 mg/mL) in 50 mM Tris-HCl, pH 8.8, and 
15 mM MgCl2 was used to cleave c-di-AMP (100 μM) at 37 °C. Reactions were 
stopped by heating up to 95 °C for 5 min, and the precipitated proteins were removed 




concentrations of 250 mM and 10 μM for KBr and coralyne, respectively. The sample 








H NMR of compounds 2.2 and 2.3 to show that the TEA cations were 
successfully removed. 




































JH1‟, H2‟ coupling constants of c-di-GMP (2.1) 
 
 
C-di-GMP (2.1), JH1‟, H2‟ coupling constant (~6.56 ppm) was extracted from COSY at 
30 °C, Row 1009; the peaks (~5.89 ppm) are due to the auto-correlation of the peak 






JH1‟, H2‟ coupling constants of 2
’




2‟-F-c-di-GMP (2.2), JH1‟, H2‟ coupling constant (~5.94 ppm) was extracted from 
COSY at 30 °C, Row 768; the peaks (~4.70 ppm) are due to the auto-correlation of 











2‟-H-c-di-GMP (2.3), JH1‟, H2‟ (H2‟‟) coupling constant (~6.30 ppm) was extracted from 






















C-di-AMP (4.1) HPLC trace 
 
HPLC condition: Merck Purosphser® STAR RP-18 column (10 × 250 mm), eluting 
with 5  20% B at 0  16 min (A: 100 mM TEAA in water; B: acetonitrile, pH 7.0), 
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